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ABSTRACT 
 
The aim of present work is to prepare floating microspheres of Abacavir sulphate using 
HPMC K100M and HPMC K4M as polymer. Floating drug delivery system have a bulk density 
less than gastric fluids and so remains buoyant in the stomach without affecting gastric emptying 
rate for a prolonged period of time. Abacavir sulphate an anti HIV drug . The short half life of 
Abacavir sulphate and multiple administration dose make Abacavir sulphate a very good 
candidate for formulation of floating drug delivery system. Floating microspheres of Abacavir 
sulphate were prepared by solvent evaporation method using HPMC K100M and HPMC K4M as 
polymer. The floating microspheres was evaluated such as micromeritic properties, percentage 
yield, invitro buoyancy, incorporation efficiency, drug polymer compatibility (IR study), 
scanning electron microscopy and drug release of microspheres. The micromeritic properties was 
found to be good and scanning electron microscopy confirmed their hollow structure with 
smooth surface. Formulation F7 prepared with combination of  HPMC K100M and HPMC K4M  
with drug which exhibited excellent micromeritic properties, percentage yield, invitro buoyancy, 
incorporation efficiency and percentage drug release 90.12 % for a period of 12 hrs. The data 
obtained in this study thus suggest that a floating microspheres of Abacavir sulphate are 
promising for sustained drug delivery which can reduce dosing frequency. 
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1. INTRODUCTION  
During the last three decade many studies have been performed concerning the 
sustained release dosage form of drugs, which have aimed at the prolongation of gastric 
emptying time (GET). The GET has been reported to be from 2 to 6 hours in humans in 
the fed state. Accordingly orally, sufficient bioavailability and prolongation of the 
effective plasma level occasionally cannot be obtained.  
Gastric emptying of dosage forms is an extremely variable process and ability to 
prolong and control the emptying time is a valuable asset for dosage forms, which reside 
in the stomach for a longer period of time than conventional dosage forms. Several 
difficulties are faced in designing controlled release systems for better absorption and 
enhanced bioavailability. One of such difficulties is the inability to confine the dosage 
form in the desired area of the gastrointestinal tract. Drug absorption from the 
gastrointestinal tract is a complex procedure and is subject to many variables. It is widely 
acknowledged that the extent of gastrointestinal tract drug absorption is related to contact 
time with the small intestinal mucosa. Thus, small intestinal transit time is an important 
parameter for drugs that are incompletely absorbed(1).  
Gastro retentive systems can remain in the gastric region for several hours and 
hence significantly prolong the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and improves solubility for drugs 
that are less soluble in a high pH environment. It has applications also for local drug 
delivery to the stomach and proximal small intestines. Gastro retention helps to provide 
better availability of new products with new therapeutic possibilities and substantial 
benefits for patients. 
 
1.1. GASTRO RETENTIVE DOSAGE FORMS (GRDF)(2) 
 
It is evident from the recent scientific and patient literature that an increased 
interest in novel dosage forms that are retained in stomach for a prolonged and 
predictable period of time exists today in academic and industrial research groups. One of 
the most feasible approaches for achieving a prolonged and predictable drug delivery in 
the GI tract is to control the gastric residence time (GRT), i.e. gastro retentive dosage 
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form (GRDF or GRDS). GRDFs extend significantly the period of time over which the 
drugs may be released. They not only prolong dosing intervals, but also increase patient 
compliance beyond the level of existing controlled release dosage form. Dosage form 
with prolonged GRT, i.e. gastro retentive dosage form (GRDF), will bring about new and 
important therapeutic options such as – 
1) This application is especially effective in sparingly soluble and insoluble 
drugs. It is known that, as the solubility of a drug decreases, the time available 
for drug dissolution becomes less adequate and thus the transit time becomes a 
significant factor affecting drug absorption. To override this problem, 
erodible, gastro retentive dosage forms have been developed that provide 
continuous, controlled administration of sparingly soluble drugs at the 
absorption site. 
2) GRDFs greatly improve the pharmacotherapy of the stomach through local  
drug release, leading to high drug concentration at the gastric mucosa. (For 
e.g. Eradicating Helicobacter pylori from the sub mucosal tissue of stomach) 
making it possible to treat stomach and duodenal ulcers, gastritis and 
oesophagitis, reduce the risk of gastric carcinoma and administer non-
systemic controlled release antacid formulations (calcium carbonate). 
3) GRDFs can be used as carriers for drugs with so-called absorption windows.  
These substances for e.g. antiviral, antifungal and antibiotic agents 
(sulphonamides, quinolones, penicillin, cephalosporin, amino glycosides, 
tetracycline etc.), are taken up only from very specific sites of the GI mucosa. 
 
1.1.1. BASIC GASTROINTESTINAL TRACT ANATOMY & 
PHYSIOLOGY(1,2,5,7,10) 
 Anatomy 
The stomach is an organ for storage and mixing. Anatomically the stomach is 
divided into 3 regions: fundus, body, and antrum (pylorus). The proximal part made of 
fundus and body acts as a reservoir for undigested material, capable of displaying a large 
expansion to accomadate food without much increase in intragastric pressure. Whereas 
the antrum is the main site for mixing motions and act as a pump for gastric emptying by 
propelling actions. The opening nearer to esophagus is called as cardiac end characterized 
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by pyrolic sphincter. Under fasting conditions the stomach is collapsed bag with residual 
volume of 50 ml and contains a small amount of gastric fluid and air.  
 Mucosa 
When stomach is empty the mucous membrane lining is thrown in longitudinal 
folds or rugae, and when full the rugae are ignored out and the surface is a smooth 
velvety appearance. There are numerous gastric glands situated below the surface in the 
mucous membrane consisting of the specialized cells that secrete gastric juice into the 
stomach. 
Nerve supply 
The sympathetic supply to the stomach is mainly from coeliac plexus and 
parasympathetic supply is from vagus nerves. Sympathetic stimulation reduces motility 
of the stomach and the secretion of the gastric juice, vagus stimulation has the opposite 
effect. 
Under the physiological conditions, the gastric absorption of the drugs are 
insignificant as a result of the limited surface area covered by a thick layer of mucosal 
coating, the lack of villi on the mucosal surface, and the short residence time of the drugs 
in the stomach. 
Blood supply 
Aterial blood is supplied to the stomach by branches of coeliae artery and venous 
drainage into the portal vein.  
Gastric juice composition 
About 2 to 3 litres of gastric juice secreted daily by specialized cells in the 
mucosa. About 60 ml with approximately 4 m mol of hydrogen ions per hour.  
It consists of, 
• Water 
• Gastric enzymes(pepsin, gastric lipase, gastrin, renin and other enzymes) 
• Mucus- glycoprotein 
• Intrinsic factor 
• Hydrochloric acid, sodium, calcium, potassium, chloride, bicarbonate, phosphate 
and sulfate. 
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 Salient Features of Upper Gastrointestinal Tract(7) 
Table 1. Features of upper GIT. 
 
Section 
Length 
(m) 
Transit time 
(h) 
pH 
Microbial 
count 
Absorbing 
surface 
area (m2) 
Absorption 
pathway 
Stomach 0.2 Variable 1-4 <103 0.1 P, C, A 
Small 
Intestine 
6-10 3 ± 1 5-7.5 103 – 1010 120-200 
P, C, A, F, I, 
E, CM 
 
Where,   
P – Passive diffusion.                             
C – Aqueous channel transport. 
A – Active transport.                            
F – Facilitated transport.  
I –   Ion-pair transport.                           
E – Entero-or pinocytosis.  
CM – Carrier mediated transport. 
Gastric pH      
 Fasted healthy subject 1.1 ± 0.15.  
 Fed healthy subject 3.6 ± 0.4. 
Volume - Resting volume is about 25-50 ml.  
 Gastric emptying and motility(6) 
Gastric emptying occurs during fasting as well as fed states. The passage of drug 
from stomach to the small intestine is called gastric emptying. It is the rate limiting step 
for drug absorption because the major site for absorption in intestine. Generally rapid 
gastric emptying increase bioavailability of the drug. Faster onset requires for drugs that 
degrade in gastric environment. Delayed gastric emptying promotes dissolution of the 
drugs, which are poorly soluble drugs and for the drugs that is majorly absorbed from 
stomach or proximal part of the intestine. 
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The pattern of motility is however distinct in the 2 states. During the fasting state 
an interdigestive series of electrical events take place, which cycle both through stomach 
and intestine every 2 to 3 hours. This is called the interdigestive myloelectric cycle or 
migrating myloelectric cycle (MMC), which is further divided into following 4 phases 
are, 
 Phase I (basal phase) lasts from 40 to 60 minutes with rare contractions.  
 Phase II (preburst phase) lasts for 40 to 60 minutes with intermittent action 
potential and contractions. As the phase progresses the intensity and 
frequency also increases gradually.  
 Phase III (burst phase) lasts for 4 to 6 minutes. It includes intense and 
regular contractions for short period. It is due to this wave that all the 
undigested material is swept out of the stomach down to the small 
intestine. It is also known as the housekeeper wave.  
 Phase IV Period of transition from phase III and phase I lasts for 0 to 5 
minutes. 
After the ingestion of a mixed meal, the pattern of contractions changes from 
fasted to that of fed state. This is also known as digestive motility pattern and comprises 
continuous contractions as in phase II of fasted state. These contractions result in 
reducing the size of food particles (to less than 1 mm), which are propelled toward the 
pylorus in a suspension form. During the fed state onset of myloelectric cycle (MMC) is 
delayed resulting in slowdown of gastric emptying rate.  
Many Scientigraphic studies determining gastric emptying rates revealed that 
orally administered controlled release dosage forms are subjected to basically 2 
complications, that of short gastric residence time and unpredictable gastric emptying 
rate. 
Gastric Transit time 
The transit time of gastrointestinal drug delivery system along GI tract is the most 
limiting physiological factor in the development of controlled- release gastrointestinal 
drug delivery systems. The pattern of GI transit depends on the fasted or fed state.  
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Fig. 1. Internal structure of stomach 
 
1.1.2. APPROACHES TO GASTRIC RETENTION(2,5) 
 
A number of approaches have been used to increase the GRT of a dosage form in 
stomach by employing a variety of concepts. These include – 
 
a) Floating Systems 
 
Floating Drug Delivery Systems(FDDS) have a bulk density lower than gastric 
fluids and thus remain buoyant in the stomach for a prolonged period of time, without 
affecting the gastric emptying rate. While the system is floating on the gastric contents, 
the drug is released slowly at a desired rate from the system. After the release of the drug, 
the residual system is emptied from the stomach. This results in an increase in the GRT 
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and a better control of fluctuations in the plasma drug concentrations. Floating systems 
can be classified into two distinct categories, noneffervescent and effervescent systems. 
 
 
Fig. 2.  Graphic of Buoyant tablet which is less dense than the stomach 
fluid and therefore remains in the fundus. 
 
b) Bio/Muco-adhesive Systems 
Bio/muco-adhesive systems are those which bind to the gastric epithelial cell 
surface or mucin and serve as a potential means of extending the GRT of drug delivery 
system (DDS) in the stomach, by increasing the intimacy and duration of contact of drug 
with the biological membrane. The surface epithelial adhesive properties of mucin have 
been well recognized and applied to the development of GRDDS based on bio/muco-
adhesive polymers. The ability to provide adhesion of a drug (or a delivery system) to the 
GI wall provides a longer residence time in a particular organ site, thereby producing an 
improved effect in terms of local action or systemic effect. 
Binding of polymers to the mucin/epithelial surface can be divided into three broad 
categories :– 
• Hydration-mediated adhesion. 
• Bonding-mediated adhesion. 
• Receptor-mediated adhesion. 
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c) Swelling and Expanding Systems 
These are the dosage forms, which after swallowing, swell to an extent that 
prevents their exit from the pylorus. As a result, the dosage form is retained in the 
stomach for a long period of time. These systems may be named as “plug type system”, 
since they exhibit the tendency to remain logged at the pyloric sphincter if that exceed a 
diameter of approximately 12-18 mm in their expanded state. The formulation is 
designed for gastric retention and controlled delivery of the drug into the gastric cavity. 
Such polymeric matrices remain in the gastric cavity for several hours even in the fed 
state. A balance between the extent and duration of swelling is maintained by the degree 
of crosslinking between the polymeric chains. A high degree of cross-linking retards the 
swelling ability of the system maintaining its physical integrity for prolonged period. 
 
d) High Density Systems 
These systems with a density of about 3 g/cm3 are retained in the rugae of the 
stomach and are capable of withstanding its peristaltic movements. A density of 2.6-2.8 
g/cm3 acts as a threshold value after which such systems can be retained in the lower part 
of the stomach. High-density formulations include coated pellets. Coating is done by 
heavy inert material such as barium sulphate, zinc oxide, titanium dioxide, iron powder 
etc. They are retained in the antrum of stomach as shown in Fig. 3. 
 
Fig. 3. Graphic of heavy tablet which is denser than the stomach fluid and therefore 
sinks to the antrum 
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e) Incorporation of Passage Delaying Food Agents 
Food excipients like fatty acids e.g. salts of myristic acid change and modify the 
pattern of thestomach to a fed state, thereby decreasing gastric emptying rate and 
permitting considerableprolongation of release. The delay in the gastric emptying after 
meals rich in fats is largelycaused by saturated fatty acids with chain length of C10-C14. 
 
f) Ion Exchange Resins 
A coated ion exchange resin bead formulation has been shown to have gastric 
retentive properties, which was loaded with bicarbonates. Ion exchange resins are loaded 
with bicarbonate and a negatively charged drug is bound to the resin. The resultant beads 
were then encapsulated in a semi-permeable membrane to overcome the rapid loss of 
carbon dioxide. Upon arrival in the acidic environment of the stomach, an exchange of 
chloride and bicarbonate ions take place. As a result of this reaction carbon dioxide was 
released and trapped in the membrane there by carrying beads towards the top of gastric 
content and producing a floating layer of resin beads in contrast to the uncoated beads, 
which will sink quickly. 
 
g) Osmotic Regulated Systems 
It is comprised of an osmotic pressure controlled drug delivery device and an 
inflatable floating support in a bioerodible capsule. In the stomach the capsule quickly 
disintegrates to release the intragastric osmotically controlled drug delivery device. The 
inflatable support inside forms a deformable hollow polymeric bag that contains a liquid 
that gasifies at body temperature to inflate the bag. The osmotic controlled drug delivery 
device consists of two components – drug reservoir compartment and osmotically active 
compartment. 
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1.1.3. APPROACHES (gastro retentive) (3,7,10) 
Several approaches have been attempted in the preparation of gastro-retentive drug 
delivery systems. This include, 
 Floating systems, 
 Bioadhesive systems,  
 Swellable systems, 
 High density systems,  
 Modified-shape systems. 
 Co-administration of gastric- emptying delaying drugs. 
 
a) Floating systems 
 Floating systems have low bulk density so that they can float on the 
gastric juice in the stomach without affecting gastric emptying. 
 
 
 
 
Fig. 4. Gastro retentive dosage forms 
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1.2. FLOATING DRUG DELIVERY SYSTEMS (1,2,7,9,10) 
Floating drug delivery system have a bulk density less than gastric fluids(less than 
1.004 g/ml) and so remain buoyant in the stomach without affecting the gastric emptying 
rate for a prolonged period of time. While the system is floating on the gastric contents, 
the drug is released slowly at the desired rate from the system. After release of drug, the 
residual system is emptied from the stomach. This results in an increased GRT and a 
better control of fluctuations in plasma drug concentration. 
The floating sustained release dosage forms present most of the characteristics of 
hydrophilic matrices and are known as ‘hydrodynamically balanced systems’ (‘HBS’) 
since they are able to maintain their low apparent density, while the polymer hydrates and 
builds a gelled barrier at the outer surface. The drug is released progressively from the 
swollen matrix, as in the case of conventional hydrophilic matrices. These forms are 
expected to remain buoyant on the gastric contents without affecting the intrinsic rate of 
emptying because their bulk density is lower than that of the gastric contents.  
 
Fig.5. Floating Tablets. 
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Fig.6. Mechanism of floating systems 
GF= Gastric fluid 
1.2.1. MECHANISM OF FLOATING SYSTEMS(7,9,10) 
Floating drug delivery systems (FDDS) have a bulk density less than gastric fluids 
and so remain buoyant in the stomach without affecting the gastric emptying rate for a 
prolonged period of time. While the system is floating on the gastric contents, the drug is 
released slowly at the desired rate from the system. After release of drug, the residual 
system is emptied from the stomach. This results in an increased GRT and a better 
control of the fluctuations in plasma drug concentration. However, besides a minimal 
gastric content needed to allow the proper achievement of the buoyancy retention 
principle, a minimal level of floating force (F) is also required to keep the dosage form 
reliably buoyant on the surface of the meal. To measure the floating force kinetics, a 
novel apparatus for determination of resultant weight has been reported in the literature. 
The apparatus operates by measuring continuously the force equivalent to F (as a 
function of time) that is required to maintain the submerged object. The object floats 
better if F is on the higher positive side. This apparatus helps in optimizing FDDS with 
respect to stability and durability of floating forces produced in order to prevent the 
drawbacks of unforeseeable intragastric buoyancy capability variations, 
             F = F buoyancy - F gravity 
 
   = (Df - Ds) gv--- (1) 
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Where,  
F = total vertical force, 
Df = fluid density, 
Ds = object density, 
v = volume and 
g = acceleration due to gravity. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.7. Mechanism of Effervescent floating systems 
 
1.2.2. ADVANTAGES OF FDDS(6) 
1. Floating dosage forms such as tablets or capsules will remains in the solution for  
       prolonged time even at the alkaline pH of the intestine. 
    2.   FDDS are advantageous for drugs meant for local action in the stomach eg    
       Antacids 
    3.   FDDS dosage forms are advantageous in case of vigorous intestinal movement                           
       and in diarrhea to keep the drug in floating condition in stomach to get a relatively         
       better response. 
   4.    Acidic substance like aspirin causes irritation on the stomach wall when come in  
      contact with it hence; HBS/FDDS formulations may be useful for the    
      administration of aspirin and other similar drugs. 
  5.    The FDDS are advantageous for drugs absorbed through the stomach eg: Ferrous 
salts, antacids. 
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1.2.3. DISADVANTAGES OF FDDS(6)  
1. Floating systems are not feasible for those drugs that have solubility or stability     
       problems in gastric fluids. 
2. Drugs such as Nifedipine, which is well absorbed along the entire GI tract and 
which undergo sig-nificant first-pass metabolism, may not be suitable candidates    
for FDDS since the slow gastric empty-ing may lead to reduced systemic 
bioavailability. Also there are limitations to the applicability of FDDS for drugs 
that are irritant to gastric mucosa. 
3. One of the disadvantages of floating systems is that they require a sufficiently 
high   level of fluids in the stomach, so that the drug dosages form float therein 
and work efficiently. 
       4.  These systems also require the presence of food to delay their gastric emptying. 
       5.  Single unit floating DDS show all or none gastric emptying phenomena 
 
1.2.4. COMPONENTS ARE USED IN PREPARATION OF FLOATING 
DRUGS(2,10) 
               Materials having a specific gravity of less than one can be used to decrease the 
hydrophilic property of formulation and hence increase buoyancy. E.g. Bees wax, fatty 
acids, long chain fatty alcohols etc. 
Polymers: The following polymers are used in the preparations of floating drugs delivery 
systems like Hydroxymethyl cellulose, Carbapol, Xanthum gum, Guar gum etc 
Inert fatty materials: Edible oils 
Effervescent agents: Sodium bicarbonate, citric acid, tartaric acid. 
Low density material: Polypropylene foam powder (Accurel MP 1000®), Calcium 
silicate etc  
 
1.2.5. METHODS FOR PREPARING FLOATING DOSAGE FORM(6) 
Following approaches can be used for preparing floating dosage forms: 
1. Using gel forming hydrocolloids such as hydrophilic gums, gelatin,            
alginates, cellulose derivatives, etc. 
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2.  Using low density enteric materials such as methacrylic polymer, cellulose   
Acetate phthalate. 
3. By reducing particle size and filling it in a capsule. 
4.  By forming carbon dioxide gas and subsequent entrapment of it in the    gel  
network. 
5. By preparing hollow micro-balloons of drug using acrylic polymer and    
filled in capsules. 
6. By incorporation of inflatable chamber which contained in a liquid e.g.  
solvent that gasifies at body temperature to cause the chambers to inflate in   
the stomach. 
The factors which govern the effectiveness of active medicaments in HBS are: 
1) Amounts of active medicament to produce therapeutic effect. 
2) Bulk density 
3) Hydrophilic and hydrophobic properties 
4) Stability in gastric fluids.  
 
1.2.6. FACTORS AFFECTING THE FLOATING DRUG DELIVERY SYSTEM(11) 
Various attempts have been made to retain the dosage form in the stomach as a 
way of increasing the retention time. These attempts include use of floating dosage forms 
(gas-generating systems and swelling or expanding systems), mucoadhesive systems, 
high-density systems, modified shape systems, gastric-emptying delaying devices and co-
administration of gastric-emptying delaying drugs. Most of these approaches are 
influenced by a number of factors that affect their bioavailability and efficacy of the 
gastro retentive system: 
• Density – gastric retention time (GRT) is a function of dosage form buoyancy      
that is dependent on the density. 
 
• Size – dosage form units with a diameter of more than 7.5 mm are reported to      
have an increased GRT compared with those with a diameter of 9.9 mm. 
 
• Caloric content – GRT can be increased by four to 10 hours with a meal that is  
high in protein and fats. 
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• Shape of dosage form – tetrahedron and ring shaped devices with a flexural 
modulus of 48 and 22.5 kilo pounds per square inch (KSI) are reported to have 
better GRT 90% to 100% retention at 24 hours compared with other shapes. 
 
• Single or multiple unit formulation – multiple unit formulations show a more 
Predictable release profile and insignificant impairing of performance due to 
failure of units, allow coadministration of units with different release profiles or 
containing incompatible substances and permit a larger margin of safety against 
dosage form failure compared with single unit dosage forms. 
 
• Fed or unfed state – under fasting conditions, the GI motility is characterized by 
periods of strong motor activity or the migrating myoelectric complex  (MMC) 
that occurs every 1.5 to 2 hours. The MMC sweeps undigested material from the 
stomach and, if the timing of administration of the formulation coincides with that 
of the MMC, the GRT of the unit can be expected to be very short. However, in 
the fed state, MMC is delayed and GRT  is considerably longer. 
 
• Nature of meal – feeding of indigestible polymers or fatty acid salts can change  
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release. 
 
 
• Frequency of feed – the GRT can increase by over 400 minutes when successive 
meals are given compared with a single meal due to the low frequency of MMC. 
 
• Gender – mean ambulatory GRT in males (3.4±0.6 hours) is less compared with  
• their age and race matched female counterparts (4.6±1.2 hours), regardless of  the 
weight, height and body surface). 
 
• Age – elderly people, especially those over 70, have a significantly longer GRT. 
 
• Posture – GRT can vary between supine and upright ambulatory states of the 
patient 
 
• Concomitant drug administration – anticholinergics like atropine and 
propantheline, opiateslike codeine and prokinetic agents like metoclopramide  and 
cisapride, can affect floating time. 
• Biological factors – diabetes and Crohn’s disease, etc. 
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1.2.7. TYPES OF FLOATING DRUG DELIVERY SYSTEM(6) 
Based on the mechanism of buoyancy, two distinctly different technologies have 
been utilized in development of FDDS that are: 
1. Effervescent System, and 
2. Non- Effervescent System 
 
1. EFFERVESCENT FDDS 
Volatile liquid containing system: 
The GRT of a drug delivery system can be sustained by incorporating an 
inflatable chamber, which contains a liquid e.g. ether, cyclopentane, that gasifies at body 
temperature to cause the fluctuation of the chamber in the stomach. The device may also 
consist of a bioerodible plug made up of Poly vinyl alcohol, Polyethylene etc. that 
gradually dissolves causing the inflatable chamber to release gas and collapse after a 
predetermined time to permit the spontaneous ejection of the inflatable systems from the 
stomach. 
Gas-generating Systems 
These buoyant delivery systems utilize effervescent reactions between carbonate / 
bicarbonate salts and citric/tartaric acid to liberate CO2, which   gets entrapped in the 
jellified hydrocolloid layer of the systems thus decreasing its specific gravity and making 
it to float over gastric content. 
 
2. NON-EFFERVESCENT FDDS 
The Non-effervescent FDDS is based on mechanism of swelling of polymer or 
bioadhesion to mucosal layer in GI tract. The most commonly used excipients in non 
effervescent FDDS are gel forming or highly swellable cellulose type hydrocolloids, 
hydrophilic gums, polysaccharides and matrix forming materials such as polycarbonate, 
polyacrylate, polymethacrylate, polystyrene as well as bioadhesive polymers such as 
Chitosan and carbopol. The various types of this system are as:  
 
 Single Layer Floating Tablets:  
They are formulated by intimate mixing of drug with a gelforming 
hydrocolloid, which swells in contact with gastric fluid and maintains bulk 
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density of less than unity. They are formulated by intimate mixing of drug with 
low-density enteric materials such as HPMC. 
 
 Bi-layer Floating Tablets:  
A bi-layer tablet contain two layer one immediate release layer which releases 
initial dose from system while the another sustained release layer absorbs gastric 
fluid, forming an impermeable colloidal gel barrier on its surface, and maintain a 
bulk density of less than unity and thereby it remains buoyant in the stomach. 
 
 Alginate Beads 
Multi-unit floating dosage forms were developed from freeze dried 
calcium alginate. Spherical beads of approximately 2.5 mm diameter can be 
prepared by dropping sodium alginate solution into aqueous solution of calcium 
chloride, causing precipitation of calcium alginate leading to formation of porous 
system, which can maintain a floating force for over 12 hours. When compared 
with solid beads, which gave a short residence time of 1 hour, and these floating 
beads gave a prolonged residence time of more than 5.5 hours. 
 
 Hollow Microspheres 
Hollow microspheres (micro balloons), loaded with drug in their outer 
polymer shells are prepared by a novel emulsion solvent diffusion method. The 
ethanol: dichloromethane solution of the drug and an enteric acrylic polymer is 
poured into an agitated aqueous solution of PVA that is thermally controlled at 40 
°C. The gas phase generated in dispersed polymer droplet by evaporation of 
dichloromethane forms an internal cavity in microsphere of polymer with drug. 
The micro balloons float continuously over the surface of acidic dissolution media 
containing surfactant for more than 12 hours. 
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1.2.8. EVALUATION OF FLOATING DRUG DELIVERY SYSTEMS(9,12) 
Various parameters that need to be evaluated in gastro retentive formulations 
which includesfloating duration, dissolution profiles, specific gravity, content uniformity, 
hardness and friabilityin case of solid dosage forms. In case of multiparticulate drug 
delivery systems particle sizeanalysis, flow properties, surface morphology are also 
performed. 
  
1. SIZE AND SHAPE EVALUATION 
The particle size and shape plays a major role in determining solubility rate of the 
drugs and thus potentially its bioavailability. The particle size of the formulation was 
determined using Sieve analysis, Air elutriation (BahcoTM) analysis, Photoanalysis, 
Optical counting method, microscope, Electroresistance counting methods (Coulter 
counter), Sedimentation techniques, Laser diffraction methods, ultrasound attenuation 
spectroscopy , Air Pollution Emissions Measurements etc. 
 
2. BUOYANCY LAG TIME 
• Buoyancy lag time (BLT): The time taken for dosage form to emerge on surface 
of medium called floating lag time (FLT) or buoyancy lag time (BLT).  
• Buoyancy time: The time during which the dosage form remains buoyant were 
measured.  
3. FLOATING TIME 
Test for buoyancy is usually performed in (SGF) Simulated Gastric Fluid 
maintained at 370˚C.The time for which the dosage form continuously floats on the 
dissolution media is termed as floating time. 
 
4. SPECIFIC GRAVITY / DENSITY 
Density can be determined by the displacement method by using benzeneas 
displacement medium. The density of the system should be less than unity to confer the 
buoyancy of the system. 
 
5. WATER UPTAKE 
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It is an indirect measurement of swelling property of swellable matrix. In this the 
weighed dosage form is placed in the dissolution medium and removed out after a regular 
time interval and weight. The changes are determined with respect to time and swelling 
index is calculated by using the formula. 
 
Swelling index = Changes in weight / Initial weight. 
 
6. IN-VITRO RELEASE STUDIES 
In vitro dissolution test is generally done by using USP paddle type apparatus. 
The dosage form is placed on the dissolution medium. But sometimes as the vessel is 
large and paddles are at bottom, there is much lesser paddle force acts on floating dosage 
form which generally floats on surface. As floating dosage form not rotates may not give 
proper result and also not reproducible results. Similar problem occur with swellable 
dosage form, as they are hydro gel may stick to surface of vessel or paddle and gives 
irreproducible results. In order to prevent such problems, various types of modification in 
dissolution assembly made are as follows. 
• To prevent sticking at vessel or paddle and to improve movement of dosage form, 
method suggested is to keep paddle at surface and not too deep inside dissolution 
medium. 
• Floating unit can be made fully submerged, by attaching some small, loose, non- 
reacting material, such as few turns of wire helix, around dosage form. However 
this method can inhibit three dimensional swelling of some dosage form and also 
affects drug release. 
 
1.2.9. LIMITATIONS(10) 
1) The major disadvantage of floating system is requirement of a sufficient high      
level of fluids in the stomach for the drug delivery to float. However this 
limitation can be overcome by coating the dosage form with the help of 
bioadhesive polymers that easily adhere to the mucosal lining of the stomach. 
2) Floating system is not feasible for those drugs that have solubility or stability  
problem in gastric fluids. 
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3) The dosage form should be administered with a minimum of glass full of 
water (200-250 ml). 
4) The drugs, which are absorbed throughout gastro-intestinal tract, which under  
go first-pass metabolism (nifedipine, propranolol etc.), are not desirable 
candidate. 
5) Some drugs present in the floating system causes irritation to gastric mucosa. 
 
1.2.10. APPLICATION OF FLOATING DRUG DELIVERY SYSTEM(12,13) 
1. Sustained Drug Delivery 
 HBS system can remain in the stomach for long periods and hence can release 
the drug over a prolonged period of time. The problem of short gastric residence time 
encountered with an oral controlled release formulation, hence, can be overcome with 
these systems. These systems have bulk density of <1, as a result of which they can float 
on the gastric contents. Recently sustained release floating capsules of nicardipine were 
developed and evaluated in vivo. The formulation compared with commercially available 
MICARD capsules using rabbits. Plasma concentration time curves showed a longer 
duration for administration (16 hours) in the sustained release floating capsules as 
compared  with conventional MICARD cap (8 hours). 
 
2. Site specific drug delivery  
These systems are particularly advantages for drugs that are specifically absorbed 
from stomach or the proximal part of the small intestine eg riboflavin, furosemide and 
misoprostal. A bilayer floating capsule was developed for local delivery of misoprostol, 
which is a synthetic analog of prostaglandin E, used as protectant of gastric ulcer caused 
by administration of NSAIDs. By targeting slow delivery of misoprostol to the stomach, 
desired therapeutic level could be achieved and drug waste could be reduced.  
 
3. Absorption Enhancement  
Drugs that have poor bioavailability because of site specific absorption from the 
upper part of the GIT are potential candidates to be formulated as floating drug delivery 
systems, thereby maximizing their absorption. A significant increase in the bioavalibiling 
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of floating dosage forms (42.9%) could be achieved as compared with commercially 
available LASIX tablet (33.4%) and enteric coated LASIX-long product (29.5%). 
 
4. Maintenance of Constant Blood Level  
These systems provide an easy way of maintaining constant blood level with an 
ease of administration and better patient compliance. 
 
1.2.11. DRUGS USED IN THE FORMULATIONS OF FLOATING DOSAGE 
FORMS (7) 
Table 2. Drugs used in FDDS 
 
S.No. Dosage forms Drugs 
1. Floating microspheres 
Aspirin, Griseofulvin, p-nitroaniline, Ibuprofen, 
Ketoprofen, Piroxicam, Verapamil, Nifedipine, 
Cholestyramine, Theophylline, Nicardipine, 
Flavoxate,Dipyridamol, Terfinadine and Tranilast 
2. Floating granules Diclofenac sodium, Indomethacin and Prednisolone 
3. Films Cinnarizine and Albendazole. 
4. Floating Capsules 
Chlordiazepoxide hydrogen chloride, Diazepam, 
Furosemide, Misoprostol, L-Dopa, Benserazide, 
Ursodeoxycholic acid, Pepstatin and Propranolol. 
5. Floating tablets and Pills 
Acetaminophen, Acetylsalicylic acid, Ampicillin, 
Amoxycillin trihydrate, Atenolol, Diltiazem, 
Fluorouracil, Isosorbide mononitrate, Para- 
aminobenzoic acid, Piretamide, Chlorpheniramine 
maleate, Aspirin, Calcium Carbonate, Fluorouracil, 
Prednisolone, Sotalol, pentoxyfilline, Theophylline 
and Verapamil hydrochloride. 
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1.3. FLOATING MICROSPHERES 
 
Fig.8. Microspheres  
 
1.3.1. DEFINITION AND GENERAL DESCRIPTION (11) 
 Microspheres can be defined as solid, approximately spherical particles ranging 
in size from 1 to 1000µm.They are made of polymeric, waxy or other protective 
materials, that is biodegradable synthetic polymers and modified natural products such as 
starches, gums, proteins, fats and waxes. The natural polymers include albumin and 
gelatin, the synthetic polymer include poly lactic acid and polyglycolic acid. The solvents 
used to dissolve the polymeric materials chosen according to the polymer and drug 
solubilities and stabilities, process safety and economic considerations. Microspheres are 
small and have large surface-to-volume ratio. At the lower end of their size range they 
have colloidal properties. The interfacial properties of microspheres are extremely 
important, often indicating their activity. 
 Polyethylene and polystyrene microspheres are two most common types of 
polymermicrospheres. Polystyrene microspheres are typically used in biomedical 
applications due to their ability to facilitate procedures such as cell sorting and immune 
precipitation. Proteins and ligands adsorbed onto polystyrene readily and permanently, 
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which makes polystyrene microspheres suitable for medical research and biological 
laboratory experiments. 
 Polyethylene microspheres are commonly used as permanent or temporaryfiller. 
Lower melting temperature enables polyethylene microspheres to create porous structures 
in ceramics and other materials. High sphericity of polyethylene microspheres, as well as 
availability of colored and fluorescent microspheres, makes them highly desirable for 
flow visualization and fluid flow analysis, microscopy techniques, health sciences, 
process trouble shooting and numerous research applications. 
Glass microspheres are primarily used as a filler and volumizer for weight 
reduction, retro-reflector for highway safety, additive for cosmetics and adhesives, with 
limited applications in medical technology .Ceramic microspheres are used primarily as 
grinding media. Microspheres varywidely in quality, sphericity, uniformity, and particle 
size and particle size distribution. The appropriate microsphere needs to be chosen for 
each unique application. 
1.3.2. SALIENT FEATURES OF MICROSPHERES(11,12) 
• Taste and odour masking 
• Conversion of  oil and other liquids, facilitating ease of handling 
• Protaction of the drug from the environment 
• Delay of volatillisation  
• Freedom from incompatibilities between drug and excipients, the buffers 
• Improvement of flow properties 
• Safe handling of taste masking 
• Dispersion of water insoluble substance in aqueous media 
• Production of sustained release, controlled release and targeted medication. 
1.3.3 ADVANTAGES(11,12) 
• They facilitate accurate delivery of small quantities of potent drug and reduced 
concentration of drug at site other than the target organ or tissue. 
• They provide protection for unstable drug before and after administration, prior to 
their availability at the site of action. 
• They provide the ability to manipulate the in vivo action of the drug, 
pharmacokinetic profile, tissue distribution and cellular interaction of the drug. 
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• They enable controlled release of drug. 
• Ex: narcotic, antagonist, steroid hormones    
• Microspheres in Vaccine delivery 
• Targeting of Drug 
• Magnetic Microspheres 
• Immunomicrospheres  
• Micro sponges: Topical Porous Microspheres 
• Imaging 
• Surface modified Microspheres 
1.3.4. DISADVANTAGES(11,12) 
• At the same time they encounter with the disadvantages of common modified 
release formulations. The release rate of controlled-release products can be altered 
by various factors including food and the rate of transit through the gut.  
• There may be some differences in the release rate from one dose to another, but 
these have been minimized by modern formulations.  
• Extended-release or controlled release products generally contain a higher drug 
load and any loss of integrity of the release characteristics of the dosage form may 
lead to potential toxic problems. Some extended-release products can be divided 
to provide half-doses, others should only be taken whole.  
• Dosage forms of this category should not be crushed or chewed as the slow-
release characteristics may be lost and toxicity may result.  
• Further larger size of extended-release products may cause difficulties in 
ingestion or transit through the gut.  
• Even though they have number of pharmacological advantages, the distal 
intestinal toxicological manifestations of sustained release and enteric-coated 
NSAID formulations should not be forgotten.  
• One consequence has been to shift the site of GI inflammation from the stomach 
to the small intestine, where damage can remain asymptomatic until more serious 
problems arise. 
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1.3.5. APPLICATIONS (13) 
The brief outline of various applications of microsphere is explained as follows: 
a. Microspheres in chemotherapy 
The most promising application of microspheres are possible to used as carriers 
for anti- tumor agents. Enhanced endocytic activity and leaky vasculature administrated 
microspheres. Stealth microspheres are prepared by coating with soluble polyoxy 
ethylene. The accumulation of non-stealth microspheres in Reticulo Endothelial System 
(RES) may also be exploited for cancer chemo-therapy. 
b. Microspheres for DNA Delivery 
Microspheres have been recently used as a delivery vehicle for the transfer of 
plasmid DNA which leads to improve the transfer of plasmid DNA and their stability in 
the bio- environment38. Truong-Le & Co workers developed a novel system for gene 
delivery based on the use of DNA-gelatin microspheres/ nanoparticles formed by salt 
induced complex coacervation of gelatin & plasmid DNA. 
c. Fluorescent microspheres 
These are made up of polystyrene or poly vinyl toluene, mono disperse system 
ranging in size from 20nm to 4µm. Preparation of fluorescent microspheres comprising, 
swelling the polymeric microsphere so that fluorescent dyes may enter the microsphere 
pores. Unswelling the polymeric microspheres so that the fluorescent dyes become 
physically entrapped in the pores39. 
d. Adjuvant effect for vaccines 
An adjuvant effect of the microspheres/nanoparticles with either matrix en- 
trapped or surface adsorbed vaccines have been demonstrated in several studies on 
substances or oral administration. “Kreuter & Co-workers” observed that Poly methyl 
methacrylate microspheres containing the influenza antigen induced significant antibody 
response. Oral delivery of antigens with microspheres may be an elegant means of 
producing an increase Immunoglobin A (Ig A) antibody response. 
e. Microspheres for Ocular delivery 
The most applications of drug loaded ophthalmic delivery systems are for 
glaucoma therapy, especially cholinergic agonists like pilocarpine. The short elimination 
half life of aqueous eye drops can be extended from a very short time (1-3 min) to 
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prolonged time (15-20 min) using microspheres which have biodegradable properties e.g. 
Poly alkyl cyano acrylate. 
f. Microspheres for Lymph targeting 
The major purpose of lymph targeting is to provide an effective anticancer 
chemotherapy to prevent the metastasis of tumor cells by accumulating the drug in the 
regional lymph node. Example:  Poly alkyl cyanoacrylate microspheres bearing 
anticancer drugs for tumor of peritoneal cavity. Poly (lactide-co-glycolide) microspheres 
for the lymphatic of diagnostic agents. 
1.3.6. TYPES OF MICROSPHERES (12) 
a. Bioadhesive microspheres 
Adhesion can be defined as sticking of drug to the membrane by using the 
sticking property of the water soluble polymers. Adhesion of drug delivery device to the 
mucosal membrane such as buccal, ocular, rectal, nasal etc can be termed as bioadhesion. 
These kinds of microspheres exhibit a prolonged residence time at the site of application 
and causes intimate contact with the absorption site and produces better therapeutic 
action. 
 
b. Magnetic microspheres 
This kind of delivery system is very much important which localizes the drug to 
the disease site. In this larger amount of freely circulating drug can be replaced by 
smaller amount of magnetically targeted drug. Magnetic carriers receive magnetic 
responses to a magnetic field from incorporated materials that are used for magnetic 
microspheres are chitosan, dextran etc. The different types are therapeutic magnetic 
microspheres and diagnostic microspheres. 
i. Therapeutic magnetic microspheres 
It is used to deliver chemotherapeutic agent to liver tumor. Drugs like proteins 
and peptides can also be targeted through this system. 
ii. Diagnostic microspheres 
It can be used for imaging liver metastases and also can be used to distinguish 
bowel loops from other abdominal structures by forming nano size particles super 
magnetic iron oxides.  
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c. Floating microspheres 
In floating types the bulk density is less than the gastric fluid and so remains 
buoyant in stomach without affecting gastric emptying rate. The drug is released slowly 
at the desired rate, if the system is floating on gastric content and increases gastric 
residence and increases fluctuation in plasma concentration. Moreover it also reduces 
chances of striking and dose dumping. One another way it produces prolonged 
therapeutic effect and therefore reduces dosing frequencies. 
d. Radioactive microspheres 
Radio immobilization therapy microspheres sized 10-30 nm is of larger than 
capillaries and gets tapped in first capillary bed when they come across. They are injected 
to the arteries that lead to tumor of interest. So all these conditions radioactive 
microspheres deliver high radiation dose to the targeted areas with- out damaging the 
normal surrounding tissues. It differs from drug delivery system, as radio activity is not 
released from microspheres but acts from within a radioisotope typical distance and the 
different kinds of radioactive microspheres are emitters.  
e. Polymeric microspheres 
The different types of polymeric microspheres can be classified as follows and 
they are biodegradable polymeric microspheres and synthetic polymeric microspheres. 
i. Biodegradable polymeric microspheres 
Natural polymers such as starch are used with the concept that they are 
biodegradable, biocompatible, and also bioadhesive in nature. Biodegradable polymers 
prolongs the residence time when contact with mucous membrane due to it’s high degree 
of swelling property with aqueous medium, results gel formation. The rate and extent of 
drug release is controlled by concentration of polymer and the release pattern in a 
sustained manner. The main drawback is in clinical use drug loading efficiency of 
biodegradable microspheres is complex and is difficult to control the drug release. 
ii. Synthetic polymeric microspheres 
The interest of synthetic polymeric microspheres are widely used in clinical 
application, moreover that also used as bulking agent, fillers, embolic particles, drug 
delivery vehicles etc and proved to be safe and biocompatible. But the main disadvantage 
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of these kinds of microspheres, are tend to migrate away from injection site and lead to 
potential risk, embolism and further organ damage. 
 
1.3.7. METHOD OF PREPARATION(12,13) 
Production of sustained release, controlled release and targeted medications re-
duce the dose dumping potential compared to large implantable devices. Different 
methods of microspheres are as follow 
 Wax coating and hot melt  
 Spray coating and pan coating  
 Coacervation  
 Spray drying  
 Solvent Evaporation  
 Precipitation  
 Freeze drying  
 Chemical and thermal cross– linking  
a. Wax coating and hot melt 
Wax may be used to coat the core particles, encapsulating the drug by dissolution 
or dispersion in molten wax. The waxy solution or suspension is dispersed by high speed 
mixing into cold solution, such as cold liquid paraffin. The mixture is agitated for at least 
one hour. The external phase (liquid paraffin) is then decanted and the microspheres are 
suspended in a non- miscible solvent and allowed to air dry. Carnauba wax and beeswax 
can be used as the coating materials and these can be mixed in order to achieve desired 
characteristics. 
b. Spray coating and pan coating spray 
Coating and pan coating employ heat- jacketed coating pans in which the solid 
drug core particles are rotated and the coating material is sprayed. The core particles are 
in size range of micrometers up to few millimeters. The coating material is usually 
sprayed at angle from the side into the pan. The process is continued until an even 
coating is completed. In addition, several batches of microspheres cab be prepared with 
different coating thickness and mixed to achieve specific controlled release pattern. 
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c. Coacervation 
This process is a simple separation of macromolecular solution into two 
immiscible liquid phases, a dense coacervate phase, which is relatively concentrated in 
macromolecules and a dilute equilibrium phase. In presence of only one macro-molecule, 
this process is referred to as simple coacervation. When two or more macromolecules of 
opposite charge are present, it is referred to as complex coacervation. Former one is 
induced by various parameters like change in temperature, addition of non-solvent or 
micro ions, which results in dehydration of macromolecules because they promote 
polymer-polymer interactions over polymer solvent interaction. These can be 
manipulated to produce microspheres with specific properties. 
d. Spray drying 
It is single step, closed- system process applicable to wide variety of materials, 
including heat-sensitive materials. The drug and polymer coating materials are dissolved 
in suitable solvent (aqueous or non-aqueous) or the drug may be present as a suspension 
in the polymer solution. Alternatively, it may be dissolved or suspended within an 
emulsion or coacervate system. For example, biodegradable polylactide microspheres can 
be prepared by dissolving the drug and the polymer in methylene chloride. The 
microsphere size is controlled by the rate of spraying, the feed rate of the polymer drug 
solution, the nozzle size, the temperature in drying and collecting chambers, and the size 
of the two chambers. The quality of the spray dried products are improved by the addition 
of plasticizers that promote the polymer coalescence and film formation and enhance the 
formation of smooth surfaced and spherical microspheres. 
e. Solvent evaporation 
In this method, the drug and the polymer must be soluble in organic solvent, 
frequently ethylene chloride. The solution containing polymer and drug may be dispersed 
in an aqueous phase to form droplets. Continuous mixing and elevated temperatures may 
be employed to evaporate the more volatile organic solvents and leave the solid polymer-
drug particles suspended in an aqueous medium. The particles are finally filtered from the 
suspension. 
f. Precipitation 
It is a variation on the evaporation method. The emulsion consists of polar 
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droplets dispersed in a non-polar medium. Solvent may be removed from the droplets by 
the use of a co solvent. The resulting increase in the polymer concentration causes 
precipitation forming a suspension of microspheres. 
g. Freeze Drying 
This technique involves the freezing of the emulsion and the relative freezing 
points of the continuous and dispersed phases are important. The continuous phase 
solvent is usually organic and is removed by sublimation at low temperature and 
pressure. Finally the dispersed phase solvent of the droplets is removed by sublimation, 
leaving polymer- drug particles. 
h. Chemical and thermal cross - linking 
Microspheres made from natural polymers are prepared by a cross-linking 
process, polymer includes gelatin, albumin, starch and dextrin. A water-oil emulsion is 
prepared, where the water phase is a solution of polymer that contains drug to be 
incorporated. The oil phase is a suitable vegetable oil or oil-organic solvent mixture 
containing an oil soluble emulsifier. Once the desired water-oil emulsion is formed, the 
water soluble polymer is solidified by thermal treatment or addition of a chemical cross-
linking agent such as glutaraldehyde to form a stable chemical cross link. 
Table 3.List of floating microspheres 
Dosage form Drug 
 Ketoprofen 
 Stavudine 
 Verapamil Hydrochloride 
 Boswellic Acid 
 Captopril  
 Metformin Hydrochloride 
Floating microspheres Famotidine  
 Ranitidine Hydrochloride 
 Ofloxacin Hydrochloride 
 Glipizide 
 Acyclovir 
 Silymarin 
 Gabapentin 
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2. LITERATURE REVIEW 
 M. NAJMUDDIN et al., studied on the Floating drug delivery system have a bulk 
density less than gastric fluids and so remains buoyant in the stomach without affecting 
gastric emptying rate for a prolonged period of time. Ketoprofen is nonsteroidal 
antiinflammatory drug with short elimination half life 1‐3 hours. The short half life of 
ketoprofen and multiple administration dose make ketoprofen a very good candidate for 
formulation of floating drug delivery system. Floating microspheres of ketoprofen were 
prepared by emulsion solvent diffusion method using Eudragit S 100 and Eudragit L 
100 as polymer. The floating microspheres was evaluated such as micromeritic 
properties, particle size, percentage yield, in vitro buoyancy, incorporation efficiency, 
drug polymer compatibility(IR study ), scanning electron microscopy and drug release 
of microsphere The micromeritic properties was found to be good and scanning 
electron microscopy confirmed their hollow structure with smooth surface. Formulation 
EU2 prepared with Eudragit S 100 drug: polymer ratio (1:2) which exhibited excellent 
micromeritic properties, percentage yield, in vitro buoyancy, incorporation efficiency 
and percentage drug release 92.26 % for a period of 12 hrs. Results show that as 
increase in drug: polymer ratio affects the particle size, percentage yield, in vitro 
buoyancy and drug release of microspheres. 
 
 YUVERJ SINGH TANWAR et al., prepared and evaluated floating microspheres of 
verapamil hydrochloride for improving the drug bioavailability by prolongation of gastric 
residence time. Cellulose acetate, acrycoat S100 and eudragit S100 microspheres loaded 
with verapamil hydrochloride were prepared by solvent diffusion evaporation method. 
The microspheres had smooth surfaces, with free-flowing and good-packing properties. 
The yield of the microspheres was up to 70.51% and cellulose acetate microspheres 
entrapped the maximum amount of the drug. Scanning electron microscopy confirmed 
their hollow structures with sizes in the range 251.80 to 350.75 µm. The prepared 
microspheres exhibited prolonged drug release and remained buoyant for more than 12 h. 
 
 SURESH FARTVAL et al., carried a research on floating microspheres using boswellic 
(BA) as model drug for prolongation of the gastric retention time. BA is a lipophilic drug 
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hence it is absorbed rapidly from the stomach and having the half-life of 6 Hrs. So it is 
suitable candidate to formulate GRDDS. The microspheres were prepared by the solvent 
evaporation method using polymers hydroxypropyl methylcellulose (HPMC) in fixed 
ratio and Ethyl cellulose in variant ratios. The shape and surface morphology of prepared 
microspheres were characterized by optical and scanning electron microscopy, 
respectively. Drug polymer compatibility study was done by TLC and IR spectroscopy. 
The Percentage yield, Particle size distribution, Buoyancy percentage, Entrapment 
Efficiency and In vitro drug release studies were performed and drug release kinetics was 
evaluated using the linear regression method. The prepared microspheres exhibited 
prolonged drug release (18h) and remained buoyant for > 12 h. The mean particle size 
increased and the drug release rate decreased at higher polymer concentration. In vitro 
studies demonstrated diffusion- controlled drug release from the microspheres. 
 
 J JOSEPHINE et al., developed the research work was to prepare and evaluate the 
floating microspheres of stavudine as a model drug for prolongation of gastric retention 
time for oral delivery. Stavudine is a synthetic analog of reverse transcriptase inhibitor 
with short half life (0.8 to 1.5hr). The floating microspheres of Stavudine were prepared 
by emulsion solvent diffusion method using Eudragit RS 100 as a rate controlling 
polymer. The floating microspheres were evaluated for micromeritic properties, particle 
size, % yield, in vitro buoyancy, incorporation efficiency and drug release. The size or 
average diameter of prepared microspheres were recognized and characterized by 
scanning electron microscopic methods. The prepared microspheres were found to be 
spherical and free flowing and remain buoyant for more than 12 hrs. The drug-loaded 
microspheres (A1) showed encapsulation efficiencies up to 88% and also showed good 
micromeritic properties for their suitability as oral dosage forms. The microspheres 
having lower densities exhibited good buoyancy effect and hence, these could be retained 
in the gastric environment for more than12 h. Thus, the present formulations would be 
capable of reducing the frequency of administration and the dose-dependent side effects 
associated with the repeated administration of conventional stavudine tablets. 
 
 AZHAR DANISH KHAN et al., developed a multi-unit gastroretentive sustained release 
dosage form of a water-soluble drug, Verapamil hydrochloride, from a completely 
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aqueous environment. avoiding the use of any organic solvent, thus releasing the drug for 
a prolonged duration of time. Emulsion gelation technique was used to prepare emulsion 
gel beads using sodium alginate as the polymer. The gel beads containing oil was 
prepared by gently mixing and homogenizing oil and water phase containing sodium 
alginate which was then extruded in to calcium chloride solution. The effects of factors 
like concentration of oil, drug: polymer ratio and alginate: pectin ratio on drug 
entrapment efficiency, floating lag time and morphology and drug release was studied. 
The use of sodium alginate and combinations of sodium alginate and pectin were used to 
study the effect on the sustaining property of the formed beads. It was found that sodium 
alginate was not sufficient to sustain the drug release at gastric pH. Instead of it, 
appropriate combination of alginate and pectin could provide the sustain release of drug. 
The results show that these beads can entrap even a water soluble drug as Verapamil 
hydrochloride in sufficient amount and also can successfully deliver the drug in stomach 
for a prolong duration of time without using any organic solvent and any time consuming 
step in the preparation. 
 
 DEVESH KAPOOR et al., studied on floating microspheres of tween80 as the 
surfactant. Differential Scanning Calorimeter (DSC) study shows that drug and other 
excipients are compatible with each other. The effects of polymers concentration on drug 
release profile were investigated. A 32 full factorial design was applied to systemically 
optimize the drug release profile. Polymer to drug ratio (X1) and stirring speed (X2) were 
selected as independent variables. The floating microspheres were characterized by and 
results obtained are % yield, particle size analysis, drug entrapment efficiency, buoyancy 
percentage, in-vitro drug release was studied for 12 hour and scanning electron 
microscopy. Accelerated stability study was also performed for three months indicated 
that optimized formulation was stable. The floating microspheres showed better result 
and it may be use full for prolong the drug release in stomach and improve the 
bioavailability. 
 
 GHODAKE J.D et al., prepared and evaluated floating microspheres with Metformin 
Hydrochloride as model drug for prolongation of gastric residence time. The 
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microspheres were prepared by the emulsification solvent diffusion technique using 
polymers Hydroxypropyl methyl cellulose K4M and Eudragit RS100. The shape and 
surface morphology of prepared microspheres were characterized by scanning electron 
microscopy, respectively. In vitro drug release studies were performed and drug release 
kinetics was evaluated using the linear regression method. Effects of the stirring rate 
during preparation, polymer concentration, solvent composition and dissolution medium 
on the size of microspheres and drug release were also observed. The prepared 
microspheres exhibited prolonged drug release (8 h). The mean particle size increased 
and the drug release rate decreased at higher polymer concentration. No significant effect 
of the stirring rate during preparation on drug release was observed. In most cases good 
in vitro floating behavior was observed and a broad variety of drug release pattern could 
be achieved by variation of the polymer and solvent ratio, which was optimized to match 
target release profile. The developed floating microspheres of metformin hydrochloride 
may be used in clinic for prolonged drug release in stomach for at least 8 hrs, thereby 
improving the bioavailability and patient compliance. 
 
 PANDEY MANISHA et al., carried out a research of famotidine floating microspheres, 
evaluation of Floating Drug Delivery System (FDDS) in vitro, prediction of the release, 
and optimization of stirring speed and polymers ratio to match target release profile was 
investigated. Floating microspheres were prepared by solvent evaporation (Oil-in-water 
emulsion) technique using hydroxylpropyl methylcellulose (HPMC) and Ethylcellulose 
(EC) as the rate controlling polymers. Particle size analysis, drug entrapment efficiency, 
surface topography, buoyancy percentage and release studies were performed. Results 
showed that the polymer ratio and stirring speed affected the size, incorporation 
efficiency and drug release of microspheres (> 12 h), floating time (> 12 hr) and the best 
results were obtained at the ratio of HPMC:EC (1:6). The mean particle size of prepared 
floating microspheres increased but the drug release rate from the microspheres 
decreased as the polymer concentration increased. The developed floating microspheres 
of famotidine may be used in clinic for prolonged drug release in stomach for at least 12 
hrs, thereby improving the bioavailability and patient compliance. 
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 PUNITHA.K et al., studied the preparation of floating microspheres of Ranitidine 
Hydrochloride with HPMC 15 cps and Eudragit E‐100 in various ratios of 1: 1, 1: 2, and 
1: 3. Floating microspheres were aimed to achieve an extended retention in the upper 
gastrointestinal tract, which may result in enhanced absorption and thereby improved 
bioavailability. The formulations were evaluated for FTIR, drug loading, % entrapment, 
particle size, SEM, buoyancy, dissolution study and the drug release kinetics. The 
enhanced floatability of the formulation and its retention in GIT may attribute for the 
increased bioavailability and decrease in frequency of administration. Comparison of 
both the polymers revealed HPMC to be a suitable candidate for sustained release. 
 
 AJAY BAGHERWAL et al., carried out research on sustained release dosage form for 
this drug. HPMC and carbomer are the polymers, used as suspending agent, viscosity 
increasing agent and tablet binder coating agents. In the present study, it was aimed to 
formulate floating tablet of ciprofloxacin HCl with HPMC and carbomer in different 
proportion (4%, 8% and 12%) by direct compression techniques using polymers lactose, 
Magnesium Sterate, talc with sodium bicarbonate. All the prepared formulation were 
found to complies with the official tests like precompression parameter like angle of 
repose and post compression parameters like Shape, tablet dimensions, hardness, 
friability test, weight variation test, floating test, content uniformity and in-vitro 
dissolution study. In-vitro release studies were carried out using USP XXII dissolution 
test apparatus. The mean percentage of ciprofloxacin released at various time intervals 
was calculated and plotted against time. The mechanism of drug release with all the 
formulations was dominantly diffusion and followed zero order kinetics. It was observed 
that the integrity of the drug is not affected by formulation procedure. The results 
revealed the drug polymer ratio showed greater drug release than other formulations. 
 
 BATHINI SREE TEJASWI., et al., studied on Floating Microspheres of 
Clarithromycin (FMC) were prepared by Solvent Evaporation Technique using ethyl 
cellulose as a polymer. The prepared microspheres were subjected to evaluation for 
particle size, incorporation efficiency, in vitro buoyancy, in vitro drug release 
characteristics and stability studies. These microspheres showed good buoyancy. The 
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formulation variables like polymer concentration and drug concentration influenced the 
in vitro drug release significantly in simulated gastric fluid (pH. 2.0). It was also noted 
that the required amount of Clarithromycin for eradication of H. pylori was significantly 
less in FMC than from corresponding Clarithromycin suspension. About 82% of the 
prepared microspheres floated in hydrochloric acid buffer solution for 12h. 71% of the 
Clarithromycin contained in the microspheres were released within 12 h in a sustained 
manner. These results suggest that FMC will be a promising drug delivery system for the 
treatment of H. pylori infection. 
 
 SHASHIKANT D.BARHATEL et al., carried out a research on gastro retentive drug 
delivery system can be prepared to improve the absorption and bioavailability of 
ketorolac trometamol by retaining the system in to the stomach for prolonged period of 
time. The floating drug delivery system of ketorolac trometamol was prepared by 
emulsion solvent diffusion method by using ethyl cellulose, HPMC K4M, Eudragit R 
100, Eudragit S 100 polymers in varying concentration. Formulations were evaluated for 
percent yield, particle size, entrapment efficiency, in vitro buoyancy and in vitro release 
studies. The optimized formulations show good buoyancy and in vitro controlled release 
of ketorolac trometamol. 
 
 ANAND GADADANAND GADAD et al., studied on floating microspheres was 
formulated using biocompatible polymers like Eudragit S100 and Ethyl cellulose in 
different proportions by solvent evaporation technique. The prepared microspheres were 
evaluated for percentage yield, micromeritic properties, particle size, morphology, drug 
entrapment, buoyancy studies, In vitro drug release studies. Practical yield of the 
microspheres was up to 76.40%. The formulated microspheres were free flowing with 
good packing properties. Scanning electron microscopy confirmed spherical structure and 
the particles were of the size range of 57.66 to 93.21µm. The microspheres with Ethyl 
cellulose showed higher buoyancy when compared with Eudragit S-100. All formulation 
showed good in vitro percent buoyancy. In vitro release studies showed cumulative % 
drug release between 75.95-88.27%. In vitro release studies demonstrated non-Fickian 
diffusion of drug from the microsphere. 
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 S. M. SARODE et al., developed glipizide floating system, as these will release the drug 
slowly in to the GIT and maintain a constant drug concentration in the serum for a longer 
period of time. Glipizide is commercially available as conventional tablet form. Single 
unit dosage form of Glipizide causes gastric irritation. To convert it in to the multiple unit 
dosage form will release the drug uniformly throughout the stomach which suppresses the 
irritation. The present study aim towards formulation and evaluation of floating 
multiparticulate drug delivery system, which can provide control release of the model 
drug. The work also aims to study various parameters affecting the behavior of floating 
multi particulate in oral dosage form. 
 
 PARMAR KUNAL VINODBHAI et al., studied on Acyclovir loaded floating 
microspheres were prepared by double emulsion solvent evaporation method. The 32 full 
factorial design was applied to optimize the formulation. The resultant microspheres were 
evaluated for average particle size, percentage encapsulation efficiency, in vitro drug 
release and model fitting kinetics. Scanning electron microscopy, Fourier transform 
infrared (FTIR) spectroscopy and differential scanning calorimeter were used to 
investigate the physical state of the drug in the microspheres. Microspheres remained 
buoyant for more than about 12 h. The results of FT-IR spectroscopy and differential 
scanning calorimeter indicated the stable character of acyclovir in microspheres and also 
revealed absence of drug polymer interaction. The in vitro drug release study showed that 
acyclovir release from the microspheres was slow and sustained for more than about 10 
h. Drug release followed Korsemeyer-peppas model. The results of factorial batches 
revealed that the concentration of ethyl cellulose and stirring speed significantly affected 
drug encapsulation efficiency and particle size of the microspheres. Thus we can 
conclude that floating microspheres can successfully be developed to sustain the drug 
release. 
 
 GD GUPTA et al., carried out a research on floating microspheres were evaluated for 
flow properties based on parameters such as angle of repose and compressibility index, as 
well as for various other physicochemical properties including particle size, incorporation 
efficiency, in vitro floatability, and in vitro drug release. The shape and surface 
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morphology of the microspheres were characterised by optical and scanning electron 
microscopy. The drug retained in the floating microparticles decreased with increase in 
ERL content. Scanning electron microscopy and particle size analysis revealed 
differences between the formulations as to their appearance and size distribution. X-ray 
and DSC examination showed the amorphous nature of the drug. Release rates were 
generally low in 0.1 N HCl especially in presence of high content of ES while in 
phosphate buffer pH 6.8, high amounts of ES tended to give a higher release rate. 
Floating ability in 0.1 N HCl, 0.1 N HCl containing 0.02% Tween 20 and simulated 
gastric fluid without pepsin was also tested. 
 
 C.SHARON KUMAR et al., prepared floating gabapentin microspheres were evaluated 
for different evaluation parameters such as percentage yield, particle size determination, 
drug content determination, Encapsulation efficiency, In-Vitro buoyancy, in-vitro drug 
release. The in vitro drug release revealed that batch C was having 75% cumulative 
release at the end of 12 th hour when compared with batch A & B ,due to increase in 
polymer concentration as seen in formulation C (1:3). The release kinetics of Gabapentin 
followed Supercase II transport diffusion. 
 
 FRAZ JAMILet al., reviewed a major constraint in oral controlled drug delivery system  
is that not all drug candidates are absorbed uniformly throughout the GIT. Some drugs 
are absorbed in a particular segment of GIT only or are absorbed to a different extent in 
various segments of GIT and diminished their bioavailability.  
 
 SUNIL KUMAR et al., studied on Floating drug delivery systems have a bulk density 
less than gastric fluids and so, remain buoyant in the stomach for a prolonged period of 
time, releasing the drug slowly at the desired rate from the system and increase the 
bioavailability of narrow absorption window drugs.  
 
 SAURABH SHARMA et al., studied on Floating Drug delivery system are designed to 
prolong the gastric residence time after oraladministration, at particular site and 
controlling the release of drug especially useful forachieving controlled plasma level as 
well as improving bioavailability.  
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 LALIT SINGH et al., reviewed about scientific and technological advancements have 
been made in the research and development of controlled release oral drug delivery 
systems by overcoming physiological adversities like short gastric residence times and 
unpredictable gastric emptying times.  
 
 DEBJIT BHOWMIK et al., studied on Floating drug delivery systems are the systems 
which are retained in the stomach for a longer period of time and thereby improve the 
bioavailability of drugs. Floating dosage systems form important technological drug 
delivery systems with gastric retentive behavior and offer several advantages in drug 
delivery.  
 
 K.P.SAMPATH KUMAR et al., studied on Treatment of gastrointestinal disorders such 
as gastro-esophageal reflux. Improved drug absorption, because of increased GRT and 
more time spent by the dosage form at its absorption site. Ease of administration and 
better patient compliance. Minimizing the mucosal irritation due to drugs, by drug 
releasing slowly at controlled rate. 
 
 HWANG SJ et al., developed of a long-term oral controlled-release dosage form has 
been difficult mainly because of the transit of the dosage form through the 
gastrointestinal (GI) tract. Several approaches to extend gastric residence time have been 
tried. The most commonly used systems are (1) intragastric floating systems, (2) high-
density systems, (3) mucoadhesive systems, (4) magnetic systems, (5) unfoldable, 
extendible, or swellable systems, and (6) superporous hydrogel systems. 
 
 PARK H et al., reviewed a concept of each approach is examined, and improvements 
that are needed for further development are discussed. Background materials in the GI 
physiology that are necessary for understanding the concept and usefulness of each 
approach are also provided. 
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3. AIM AND OBJECTIVES 
The aim of the present work was to formulate and evaluate sustained release 
floating microspheres of Abacavir Sulphate. 
  
Abacavir Sulphate is used to in combination with other antiretroviral agents, are 
indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Existing 
marketed products of the formulation has a dose of 300mg with dosing frequency of two 
to three times a day and very shorter biological half-life of about 1.54±0.63hour. 
 
Further a floating sustained release microsphere has been endeavored by 
employing polymer combination system to achieve effective plasma concentration with 
reduced side effects. 
 
Floating drug delivery system have a bulk density less than gastric fluids and so 
remains buoyant in the stomach without affecting gastric emptying rate for a prolonged 
period of time. 
 
Floating microspheres of Abacavir Sulphate for improving the drug 
bioavailability by prolongation of gastric residence time. 
 
Solubility of the selected drug decrease with increase in pH making stomach 
better site of absorption. Hence an attempt has been made to formulate a GI floating 
microsphere of the selected drug. Floating microspheres helps in retaining the 
microspheres in stomach fluids for longer duration and better absorption with site 
specificity.   
 
Formulation techniques involved solvent evaporation method and optimization of 
stirring speed technique and hydroxylpropyl methylcellulose (HPMC) as the rate 
controlling polymers. 
 
CHAPTER-5                                                                                PLAN OF WORK  
 
    
Dept. of Pharmaceutics                42         J.K.K.Nattraja College of Pharmacy 
 
4. PLAN OF WORK 
I. Pre formulation studies 
a) Organoleptic properties 
b) Flow properties 
c) Bulk density 
d) Tapped density 
e) Measurement of powder compressibility 
f) Melting point 
g) pH of the solution 
h) Solubility 
i) Drug excipient compatibility studies 
j) Calibration curve of Abacavir Sulphate 
II. Formulation of Abacavir Sulphate floating microspheres 
III. Evaluation of Abacavir Sulphate floating microspheres  
a)  Micromeritic properties 
i)   Angle of repose 
ii)  Determination of bulk density and tapped density 
iii) Measurement of compressibility index and Hausner ratio 
b)  Percentage yield of microspheres 
            c) Drug entrapment  
            d)  Buoyancy studies 
            e)  Invitro dissolution studies 
            f)  Kinetics of drug release 
            g) IR spectroscopy(Drug excipient compatibility) 
            h) Scanning electron microscopy 
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5. DISEASE PROFILE (14,15) 
Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI). It works 
by slowing down the growth of HIV, the virus that causes AIDS. Abacavir is used in 
combination with other drugs to treat human immunodeficiency virus (HIV) infection. 
It’s approved for adults and children who are at least 3 months old. Abacavir doesn’t cure 
HIV, but it may help to control it. Abacavir works by blocking an enzyme called reverse 
transcriptase.  
HIV: 
HIV is a virus that attacks the immune system, which is our body’s natural 
defence against illness. The virus destroys a type of white blood cell in the immune 
system called a T-helper cell, and makes copies of itself inside these cells. T-helper cells 
are also referred to as CD4 cells. As HIV destroys more CD4 cells and makes more 
copies of itself, it gradually breaks down a person’s immune system. This means 
someone living with HIV, who is not receiving treatment, will find it harder and harder to 
fight off infections and diseases. 
Fig.No.9: Structure of HIV Virus 
  
If HIV is left untreated, it may take up to 10 or 15 years for the immune system to 
be so severely damaged it can no longer defend itself at all. However, the speed HIV 
progresses will vary depending on age, health and background. Human 
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immunodeficiency virus (HIV) needs this enzyme to make copies of itself. In 2015 about 
37.3 million people were living with HIV and it resulted in 1.2 million deaths. 
Fig.No.10: Symptoms of AIDS 
 
Signs and Symptoms: 
Symptoms of early HIV infection: 
Many people with HIV have no symptoms for several months to even years after 
becoming infected. Others may develop symptoms similar to flu, usually 2-6 weeks after 
catching the virus. 
The symptoms of early HIV infection may includes, fever, chills, joint pain, 
muscle aches, sore throat, sweats (particularly at night), enlarged glands, a red rash, 
tiredness, weakness, unintentional weight loss. 
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Asymptomatic HIV 
In many cases, after the initial symptoms disappear, there will not be any further 
symptoms for many years. During this time, the virus carries on developing and 
damaging the immune system and organs. Without being on medications to stop HIV's 
replication, this process can take up to 10 years on average. The infected person often 
experiences no symptoms, feels well, and appears healthy. 
Late-stage HIV infection 
If left untreated, HIV weakens the ability to fight infection. The person becomes 
vulnerable to serious illnesses. This stage of infection is known as AIDS. 
Symptoms of late-stage HIV infection may include: 
blurred vision, diarrhea, which is usually persistent or chronic, dry cough, fever of above 
100 °F (37 °C) lasting for weeks, night sweats, permanent tiredness, shortness of breath 
(dyspnea), swollen glands lasting for weeks, unintentional weight loss,white spots on the 
tongue or mouth,. 
During late-stage HIV infection, the risk of developing a life-threatening illness is 
much greater. Life-threatening illnesses may be controlled, avoided and/or treated with 
proper medications, often including HIV treatment. 
Causes:  
HIV is a retrovirus that infects the vital organs and cells of the human immune 
system. 
Treatment:  
• There is currently no cure for HIV or AIDS. Treatments can slow the course of 
the condition - and allow most infected people the opportunity to live a long and 
relatively healthy life. 
• Earlier HIV antiretroviral treatment is crucial - it improves quality of life, extends 
life expectancy, and reduces the risk of transmission, according to the World 
Health Organization's guidelines issued in June 2013. 
• Currently, there is no vaccine or cure for HIV, but treatments have evolved which 
are much more effective and better tolerated - they can improve patients' general 
health and quality of life considerably, in as little as one pill per day.  
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Table. No. 4: Classification of Antiretroviral Drugs: 
Class  Drug  
NRTIs  Zidovudine  
Stavudine didanosine  
Abacavir  
Tenofovir  
NNRTIs  Efavirenz  
Nevirapine  
Etravirine  
Rilpivirine  
"QUAD"  elvitegravir, cobicistat, emtricitabine, and tenofovir 
disoproxil fumarate  
Protease Inhibitors  All PIs  
Atazanavir  
Indinavir  
Darunavir  
Fosamprenavir  
Nelfinavir  
Lopinavir/ ritonavir  
Tipranavir  
Entry inhibitors  Enfuvirtide  
Chemokine coreceptor 
antagonists  
Maraviroc  
Integrase inhibitors  Raltegravir  
Elvitegravir/cobicistat  
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6. DRUG PROFILE (15,16,17,18.19) 
Drug: Abacavir sulfate 
Description(15,16) 
Abacavir sulfate is a nucleoside analog reverse transcriptase inhibitor (NRTI). It 
works by slowing down the growth of HIV, the virus that causes AIDS. Abacavir is used 
in combination with other drugs to treat human immunodeficiency virus (HIV) infection. 
It’s approved for adults and children who are at least 3 months old. Abacavir doesn’t cure 
HIV, but it may help to control it. Abacavir works by blocking an enzyme called reverse 
transcriptase.  
 
Structural formula 
 
Systemic (IUPAC) name 
[(1S,4R)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl] methanol. 
 
Chemical data (17) 
Formula                        : C14H18N6O 
Molecular weight         : 286.339 g/mol. 
CAS Registry number  : 136470-78-5 
Melting point                : 165 °C 
Water Solubility            : 1.21 mg/mL or 77 mg/mL (sulfate salt) 
 
 
Physical state  
 White to off-white Powder, solid Form. 
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Solubility 
 Abacavir sulfate occurs as white powder. Soluble in Water, DMSO (< 1 mg/ml at 
25° C), ethanol (< 1 mg/ml at 25° C), and methanol. 
 
Mechanism of action(15) 
 Abacavir is a carbocyclic synthetic nucleoside analogue and an antiviral agent. 
Intracellularly, abacavir is converted by cellular enzymes to the active metabolite 
carbovir triphosphate, an analogue of deoxyguanosine-5'-triphosphate (dGTP). Carbovir 
triphosphate inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing 
with the natural substrate dGTP and by its incorporation into viral DNA. Viral DNA 
growth is terminated because the incorporated nucleotide lacks a 3'-OH group, which is 
needed to form the 5′ to 3′ phosphodiester linkage essential for DNA chain elongation. 
 
Pharmacokinetics (18) 
ABSORPTION: 
Rapid and extensive after oral administration (83% bioavailability, tablet).            
Moderate (approximately 50%).  
BINDING: 
Binding of abacavir to plasma protein was independent of concentration.  
METABOLISM: 
Hepatic, by alcohol dehydrogenase and glucuronosyltransferase to a 5′-carboxylic 
acid metabolite and 5′-glucuronide metabolite, respectively. These metabolites have no 
antiviral activity. Abacavir is not significantly metabolized by cytochrome P450 
enzymes. 
EXCRETION:  
           1.2% was excreted in the urine as abacavir, 30% as the 5′-carboxylic acid 
metabolite, 36% as the 5′-glucuronide metabolite, and 15% as unidentified minor 
metabolites in the urine. Fecal elimination accounted for 16% of the dose. Renal 
excretion of unchanged abacavir is a minor route of elimination in humans.  
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Indications and usage 
 For the treatment of HIV-1 infection, in combination with other antiretroviral 
agents. 
 
Drug category: Antiretroviral agents 
 
Dosage and administration 
Adults : 300 mg orally twice a day or 600 mg orally once a day. 
Infants & Child Dose:  
3 months or older: 
Oral solution: 8 mg/kg orally twice a day or 16 mg/kg orally once a day 
Maximum dose: 600 mg/day 
Tablets: 
14 to less than 20 kg: 150 mg orally twice a day or 300 mg orally once a day 
20 to less than 25 kg: 150 mg orally in the morning and 300 mg in the evening, or 450 
mg orally once a day 
25 kg or more: 300 mg orally twice a day or 600 mg orally once a day 
Dosage forms: Tablets 
Special precautions(19) 
Patient information: 
Serious and sometimes fatal hypersensitivity reactions (with multiple organ 
involvement) reported with this drug. Patients with the human leukocyte antigen subtype 
B*5701 (HLA-B*5701) allele.  
Pediatric Use 
 The safety and effectiveness of abacavir have been established in pediatric 
patients aged 3 months and older. 
Adverse reactions  
Commonly reported side effects of abacavir include: arthralgia, cough, fatigue, 
lethargy, myalgia, pruritus, vomiting, chills, and malaise.  
Other side effects include: hypersensitivity, pharyngitis, and tachypnea. See 
below for a comprehensive list of adverse effects.  
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Over dosage 
There is no known specific treatment for overdose with abacavir. If overdose 
occurs, the patient should be monitored and standard supportive treatment applied as 
required. It is not known whether abacavir can be removed by peritoneal dialysis or 
hemodialysis. 
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7. EXCIPIENTS PROFILE 
7.1. SODIUM ALGINATE(24,25) 
Nonproprietary Names   
Sodium alginate (BP) 
Natrii alginas (PhEur) 
Sodium alginate (USPNF) 
 
Synonyms  
Algin, alginic acid, sodium salt, E401, Kelcosol, Keltone, Protanal, sodium 
polymannuronate. 
 
Chemical Name and CAS Registry Number 
           Sodium alginate [9005-38-3] 
 
Empirical Formula and Molecular Weight 
Sodium alginate consists chiefly of the sodium salt of alginic acid, which is a 
mixture of polyuronic acids composed of residues of D-mannuronic acid and L-guluronic 
acid. 
The block structure and molecular weight of sodium alginate samples has been 
investigated. 
 
Description 
Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-
brown colored powder. 
 
Solubility 
Practically  insoluble in ethanol (95%), ether, 
chloroform, and ethanol/water mixtures in which  the ethanol 
content is greater than 30%. Also, practically insoluble in 
other organic solvents and  aqueous acidic solutions in which 
the pH is less than 3. Slowly soluble in water, forming a  
viscous colloidal solution. 
Structural Formula (25) 
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Viscosity: 20–400 mPa s . 
Loss on drying ≤15.0% 
Stability and Storage Conditions 
Sodium alginate is a hygroscopic material, although it is stable if stored at low 
relative  humidities and a cool temperature. Aqueous solutions of sodium alginate are 
most stable at ph 4–10. The bulk material should be stored in an airtight container in a 
cool, dry place. 
Incompatibilities 
Sodium alginate is incompatible with acridine derivatives, crystal violet, 
phenylmercuric acetate and nitrate, calcium salts, heavy metals, and ethanol in 
concentrations greater than 5%. Low concentrations of electrolytes cause an increase in 
viscosity but high electrolyte concentrations cause salting-out of sodium alginate; salting-
out occurs if more than 4% of sodium chloride is present. 
 
Safety 
It is generally regarded as a nontoxic and nonirritant material, although excessive 
oral consumption may be harmful. 
7.2. HYDROXYPROPYL METHYLCELLULOSE24,27 
Synonyms 
 Cellulose, hydroxypropyl methyl ether, HPMC, methocel, metolose, and 
pharmacoat 
Empirical Formula 
 HPMC is a partially o-methylated and o-(2-hydroxypropylated) cellulose. It is 
available in several grades, which vary in viscosity and extent of substitution. 
Molecular Weight 
 10,000 – 15,00,000 
Description 
 HPMC is an odorless and taste less, white or creamy white colored fibrous or 
granular powder. 
Functional Category 
 Coating agent, film-former, stabilizing agent, suspending agent, tablet binder, 
viscosity-increasing agent 
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Structural Formula (27) 
 
Where R is H, CH3, or CH3CH (OH) CH2 
 
Applications in Pharmaceutical Formulation 
 HPMC is widely used in oral and topical pharmaceutical formulations. In oral 
product it is primarily used as a tablet binder, in film coating and as an extended release 
tablet matrix. Concentration of between 2-5% w/w may be used as a binder either in wet 
or in dry granulation process. High viscosity grades may be used to retard the release of 
water-soluble drug from a matrix. Lower viscosity grades are used in aqueous film 
coating while higher viscosity grades are used with organic solvents. 
Solubility 
 Soluble in cold water, forming a viscous colloidal solution, practically insoluble 
in chloroform, ethanol, and ether, but soluble in mixture of ethanol and dichloromethane, 
and mixture of methanol and dichloromethane. 
Stability and Storage Conditions 
 HPMC is a stable material although it is hygroscopic after drying. Solutions are 
stable between pH 3-11. Increasing temperature reduces the viscosity of solutions. It 
undergoes a reversible sol to gel transformation upon heating and cooling respectively. 
 HPMC powder should be stored in a well-closed container, in a cool, dry place. 
Incompatibilities 
 It is incompatible with some oxidizing agent. Since it is nonionic, it will not 
complex with metallic salts and ionic organics to form insoluble precipitates. 
Safety 
It is generally regarded as a nontoxic and non-irritant material although excessive 
oral consumption may have a laxative effect. 
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7.3. SODIUM CARBOXY METHYL CELLULOSE(24,28) 
Nonproprietary Names 
Carmellose sodium (BP)  
Carmellose sodium (JP)  
Carmellosum natricum (PhEur)  
Carboxymethylcellulose sodium (USP) 
 
Synonyms 
Akucell, Aquasorb, Blanose, cellulose gum, E466, Finnfix, Nymcel, SCMC, 
sodium cellulose glycolate , Tylose CB. 
 
Chemical Name and CAS Registry Number 
Cellulose, carboxymethyl ether, sodium salt [9004-32-4] 
 
Empirical Formula and Molecular Weight 
Carboxymethyl cellulose sodium as the sodium salt of polycarboxy methyl ether 
of cellulose. Molecular weight is 90 000–700 000. 
 
Structural Formula (28) 
 
Description 
Sodium Carboxy methyl cellulose occurs as a white to almost white, odorless, 
granular powder. 
Solubility 
Practically insoluble in acetone, ethanol (95%), ether, and toluene. Easily 
dispersed in water at all temperatures, forming clear, colloidal solutions. 
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Moisture content 
It contains less than 10% water. Sodium carboxy methyl cellulose is hygroscopic 
and absorbs significant amounts of water at temperatures up to 378°C at relative 
humidity’s of about 80%. 
 
Viscosities: 5–13 000 mPas 
 
 Density:    Density (bulk): 0.52 g/cm3 
                   Density (tapped): 0.78 g/cm3 
 
Melting point: browns at approximately 2278°C, and chars at approximately 2528°C. 
 
Loss on drying: ≤10.0% 
 
Functional Category 
Coating agent, stabilizing agent, suspending agent, tablet and capsule disintegrate, 
tablet binder, viscosity-increasing agent, water-absorbing agent. 
 
Applications in Pharmaceutical Formulation or Technology 
Sodium Carboxy methyl cellulose is widely used in oral and topical 
pharmaceutical formulations, primarily for its viscosity increasing properties. 
Sodium Carboxy methyl cellulose is additionally one of the main ingredients of 
self-adhesive ostomy, wound care, and dermatological patches, where it is used as a 
muco-adhesive and to absorb wound exudates or transepidermal water and sweat. 
Encapsulation with sodium carboxy methyl cellulose can affect drug protection and 
delivery. Its use as a cytoprotective agent. 
 
Sodium Carboxymethylcellulose is also used in cosmetics, toiletries, surgical 
prosthetics, and incontinence, personal hygiene, and food products. 
Incompatibilities 
Sodium Carboxymethylcellulose is incompatible with strongly acidic solutions 
and with the soluble salts of iron and some other metals, such as aluminum, mercury, and 
zinc. Precipitation may occur at pH <2, and also when it is mixed with ethanol (95%). 
 
CHAPTER-7                                                                   EXCIPIENTS PROFILE  
   
Dept. of Pharmaceutics               56          J.K.K.Nattraja College of Pharmacy 
 
Stability and Storage Conditions 
Sodium Carboxymethylcellulose is a stable, although it is slightly hygroscopic. 
The bulk material should be stored in a well-closed container in a cool, dry place 
 
Safety 
Sodium Carboxymethylcellulose is used in oral, topical, and some parenteral 
formulations. It is generally regarded as a nontoxic and nonirritant material although 
excessive consumption may have laxative effect. 
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8. MATERIALS AND INSTRUMENTS 
8.1. Materials used   
Table.No.5 :  Materials used 
S. No MATERIALS 
 
SUPPLIERS/MANUFACTURERS 
1 Abacavir sulfate Molecules India Pvt Ltd, Chennai 
2 Sodium alginate s.d.fine chem. Ltd. Mumbai 
3 Sodium carboxy methyl cellulose s.d.fine chem. Ltd Mumbai 
4 Hydroxy propyl methyl cellulose K4M Otto chem. Laboratories Pvt.Ltd 
5 Hydroxy propyl methyl cellulose K100M Otto chem. Laboratories Pvt.Ltd 
6 Sodium phosphate dibasic dehydrate RANKEM,RFCL Ltd, New Delhi 
7 Potassium dihydrogen ortho phosphate RANKEM,RFCL Ltd, New Delhi 
8 Sodium chloride RANKEM,RFCL Ltd, New Delhi 
9 Paraffin liquid colorless light Molychem, Mumbai 
10 Polysorbate 80 (tween 80) Sisco Research laboratories Pvt.Ltd. 
11 Dichloromethane RANKEM,RFCL Ltd, New Delhi 
12 Methanol Merck  Specialities Pvt.Ltd, Mumbai 
13 n-hexane s.d.fine chem. Ltd, Mumbai 
 
 
 
 
 
CHAPTER-8                                                     MATERIALS AND INSTRUMENTS  
   
Dept. of Pharmaceutics              58           J.K.K.Nattraja College of Pharmacy 
 
8.2 Instruments used 
Table.No.6 :  Instruments used 
S. No INSTRUMENTS SUPPLIERS/MANUFACTURERS 
1 Digital Balance Wensar PGB - 300 
2 UV-Visible Spectrophotometer LAB INDIA UV 3000+ 
3 Dissolution Test Apparatus 
Labindia Analytical Instruments Pvt 
Ltd. Mumbai , Model-DISSO 2000 
4 Temperature controller(hot air oven) GABAKS  
5 pH Meter Chemline digital pH meter, CL-110 
6 Stirrer Remi Laboratory stirrer 
7 FTIR BRUKER HTS-XT 
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9. PREFORMULATION 
 Preformulation testing is an investigation of physical and chemical properties of a 
drug substance alone and when combined with excipients. It is the first step in the 
rational development of dosage forms. 
 Preformulation studies relate to pharmaceutical and analytical investigation 
carried out in supporting formulation development efforts of the dosage forms. 
       The following preformulation studies were performed for obtained sample of drug.       
 
9.1. ORGANOLEPTIC PROPERTIES  
9.1.1. Color and nature 
 Transferred small quantity of the sample on a white piece of paper spreaded the 
powder and examined visually. 
9.1.2. Taste and odour 
Very less quantity of Abacavir sulfate was used to get taste with the help of 
tongue as well as smelled to get the odor. 
 
9.2. PHYSICAL CHARACTERISTICS 
9.2.1. Flow properties  
The flow properties of powder are critical for an efficient microsphere preparing. 
If the drug is identified at pre formulation stage to be “poorly flowable” the problem can 
be solved by selecting appropriate excipients. Angle of repose is defined as the maximum 
angle possible between the surface of a pile of the powder and the horizontal plane. 
Procedure 
 A funnel was kept vertically in a stand at a specified height above a paper placed 
on a horizontal surface. The funnel bottom is closed and 10gm of sample powder is filled 
in funnel. Then funnel was open to release the powder on the paper to form a smooth 
conical heap, is found by measuring in a different directions. The height of the heap was 
measured by using scale. The values of angle of repose are calculated by using the 
following formula.  
 
 
 Where,  
θ=  (h/r) 
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θ = Angle of the repose 
            h = Height of the heap 
            r = Radius of the heap 
 
                                     Table 7.  ANGLE OF REPOSE LIMITS 
ANGLE OF REPOSE  FLOWABILITY 
<25 Excellent 
25-30 Good 
30-40 Passable 
>40 Very poor 
 
9.2.2. Bulk density 
Bulk density is the ratio of mass of powder to the bulk volume. Bulk density 
largely depends on particular shape as the particle become more spherical in shape, bulk 
density is increases. 
             Bulk density is determined by measuring the volume of a known mass of a 
powder sample that has been passed through a screen into a graduated cylinder. 
Procedure 
             A known quantity of powder was poured into measuring cylinder carefully level 
the powder without compacting , if necessary and read the unsettled apparent value. 
Calculate the bulk density, in gm per ml, by the formula. 
 
= m/  
 
Where,  
= Bulk density  
              m = mass of powder 
= initial/bulk volume 
The results are shown in results and discussion. 
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9.2.3. Tapped density 
Tapped density is the ratio of mass of powder to the tapped volume. 
 
Procedure 
A quantity 5gm of the powder (W) from each formula was introduced in to a 25ml 
measuring cylinder. After the initial volume was observed, the cylinder was allowed to 
fall under its own weight on to a hard surface from the height of  2.5 cm at 2 sec 
intervals. The tapping was continued until no further change in volume was noted. 
Calculate the tapped density, in gm per ml, by the formula. 
  
= m/  
Where, 
   = Tapped density 
m     = Mass of the powder 
 = Final/tapped volume 
 
9.3.1. Measurement of powder compressibility 
The compressibility index is measures of the propensity of a powder to be 
compressed. As such, they are measures relative importance of inter particulate 
interactions. In a free flowing powder, such interactions generally less and tapped 
densities will be closer in value. For poorer flowing materials, there are frequently greater 
inter particulate interactions, and a greater difference between bulk and tapped densities 
will be observed. These differences are reflected in the compressibility index calculated 
by the formula. 
 
                                                      Tapped density-Initial bulk density 
                     %compressibility= x 100 
                         (Carr’s index)               Tapped density 
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Table 8.  Compressibility index limits. 
% Compressibility Flow ability 
5-12 Excellent 
12-16 Good 
18-21 fair 
23-25 poor 
33-38 Very poor 
More than 40 Very, very poor 
 
9.3.2. Hausner ratio 
         It is the ratio of volume of tapped volume is tapped density to bulk density 
 
Hausner ratio = /   or  / 
 
Table 9. Hausner Ratio index limits 
Hausner Ratio Flowability 
1.2-1.3 Excellent 
1.3-1.4 Good 
1.4-1.5 Fair 
1.3-1.4 Poor 
 
9.3.3. Melting point 
It is one of the parameters to judge the purity of crude drug. In case of pure 
chemicals, melting points are very sharp and constant. 
Procedure 
A small quantity of powder was placed into a fusion tube. That tube is placed in 
the melting point apparatus containing castor oil. The temperature of the castor oil was 
gradual increased automatically and read the temperature at which powder started to melt 
and the temperature when all the powder gets melted. The results are shown in results and 
discussion. 
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9.4. SOLUTION PROPERTIES 
9.4.1. pH of the solution 
Weighed and transferred accurately about 1.0 g of sample in a 200ml clean and 
dried beaker, dissolved in carbondioxide free water and made up the volume to 100ml 
with same solvent, mixed.  Read the pH of freshly prepared solution by using 
precalibrated pH meter. The results are shown in results and discussion. 
 
9.4.2. Solubility 
A semi quantitative determination of the solubility was made by adding solvent in 
small incremental amount to a test tube containing fixed quantity of solute of vice versa. 
After each addition, the system is vigorously shaken and examined visually for any 
undissolved solute particles. The solubility is expressed in terms of ratio of solute and 
solvent. The results are shown in results and discussion. 
 
9.5. IDENTIFICATION OF DRUG AND COMPATABILITY STUDY 
9.5.1. Drug –excipient compatibility studies 
 In the tablet dosage form the drug is in intimate contact with one or more 
excipients; the latter could affect stability of the drug. Knowledge of drug-excipient 
interactions is therefore very useful to the formulator in selecting appropriate excipients. 
This information is already be in existence for known drugs. For new drugs or new 
excipients, the pre formulations scientist must generate the needed information. 
By physical observation 
It was determined as per procedure given in method section the following table 
illustrated the result. 
 
Table 10. Physical compatibility studies 
Test Observation Inference 
Physical compatibility No change of color These materials are 
compatible for formulation 
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Procedure by FT-IR Studies 
The IR spectrums of Abacavir sulfate with excipients were taken by preparing dispersion 
in dry potassium bromide under dry condition. Superimposed these spectra. The 
transmission minima (absorption maxima) in the spectra obtained with the sample in 
corresponded in position and relative size to those in the spectrum obtained with the 
standards. 
 
9.6 UV SPECTROSCOPIC METHOD FOR ANALYSIS OF ABACAVIR 
SULFATE 
Preparation of stock solution 
Weighed accurately 100mg of drug and transferred it to 100ml volumetric flask, 
then add water and the volume was made up to 100ml with water. 
Preparation of standard solution 
Then pipette out 1ml from above solution in a 10ml volumetric flask and made 
the volume with water to 10ml. From standard stock solution 0.2ml, 0.4ml, 0.6ml, 0.8ml 
and 1ml solution was pipette out in five 10ml volumetric flasks and make up the volume 
with water to get 2µg, 4µg, 6µg, 8µg and 10 µg/ml concentration. 
 
CALIBRATION CURVE OF ABACAVIR SULFATE 
Measured the absorbance of the above prepared standard solution at 296 nm . 
plotted a graph of concentration ( in µg/ml) on X axis and absorbance ( in nm ) on Y axis 
                                   Table 11. Calibration curve for Abacavir sulfate 
S.No. Concentration(µg/ml) Absorbance (nm) 
1 0 0 
2 2 0.152 
3 4 0.279 
4 6 0.392 
5 8 0.514 
6 10 0.623 
Slope 0.0632  
 
0.9987  
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Fig.11. Calibration curve for Abacavir sulfate 
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10. FORMULATIONS OF ABACAVIR SULFATE FLOATING 
MICROSPHERES 
 
Table 12. FORMULATIONS 
INGREDIENTS in 
mg 
FORMULATION BATCHES 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Abacavir sulfate 1000 1000 1000 1000 1000 1000 1000 1000 1000 1000 
 
HPMC K4M 
 
1000 - - - 500 500 500 - - - 
 
Sodium alginate 
 
- 1000 - - 500 - - 500 500 - 
 
Sodium  CMC 
 
- - 1000 - - 500 - 500 - 500 
 
HPMC K100M 
 
- - - 1000 - - 500 - 500 500 
 
Methanol 
 
5 5 5 5 5 5 5 5 5 5 
 
Dichloromethane 
 
5 5 5 5 5 5 5 5 5 5 
 
Floating microspheres were prepared by the solvent evaporation method using 
1000 mg of Abacavir sulfate and with different polymer as shown in Table, were 
dissolved in methanol (5 ml), dichloromethane (5 ml) with vigorous agitation to form 
uniform drug polymer dispersion. This was slowly poured into the dispersion medium 
consisting of light liquid paraffin (100ml) containing 1.1% tween 80. The system is 
stirred using propeller at 1000 rpm at room temperature for 1hr 30 min – 2 hr. The liquid 
paraffin was decanted and the microparticles were separated by filtration through a 
whatmann filter paper, was head thrice with 180 ml of n-Hexane and air dried for 6-8 hrs.                               
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12.a                                                       12.b 
Fig. 12.a : Preparation of Microspheres; 12.b : after drying microspheres 
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11. EVALUATION OF FLAVOXATE HCL FLOATING 
MICROSPHERES 
a) Micromeritic properties  
i) Angle of repose 
5 gms of the sample was taken in a funnel fixed in a holder (6 cm) above the 
surface at an appropriate height and graph of sheet was placed below the funnel. The 
sample was passed through the funnel slowly. The height of the powder heap formed was 
measured. The circumference of the heap formed was drawn with a pencil on the graph 
paper. The radius was measured and angle of repose was determined using the above 
formula. This was repeated five times for a sample. 
 
Where, 
h = height  
r = radius 
θ = angle of repose 
The results are given in results and discussion. 
ii) Determination of bulk density and tapped density 
A quantity 5gm of the powder (W) from each formula was introduced in to a 
25ml measuring cylinder. After the initial volume was observed, the cylinder was 
allowed to fall under its own weight on to a hard surface from the height of 2.5 cm at 2 
sec intervals. The tapping was continued until no further change in volume was noted. 
The bulk density and tapped density were calculated using the following the formula 
     Bulk density ( = m/  
  Tapped density( = ) = m/  
 
Where, 
m = mass of the powder 
 = initial or bulk volume 
   = final or tapped volume  
The results are given in results and discussion. 
θ= (h/r) 
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iii) Measurement of compressibility index and Hausner ratio 
           Compressibility index and Hausner ratio are measured by using the following 
formula 
     Tapped density-Intial bulk density 
%compressibility= x 100 
                    (carr’s index)                        Tapped density 
 
The result is given in in results and discussion. 
 
Hausner ratio= /  
Where, 
   = initial or bulk volume 
   = final or tapped volume 
 The results are given in results and discussion. 
 
b) Percentage yield of microspheres 
The prepared microspheres of all batches were accurately weighed. The weight 
quantity of prepared microspheres was divided by the total amount of all the excipients 
and drug used in the preparation of the microspheres, which give the total percentage 
yield of floating microspheres. It was calculated by using following equation, 
                Actual yield of product 
Percentage yield = X 100 
              Total weight of excipients and drug 
The results are given in results and discussion. 
 
c) Drug entrapment  
According to dose 100mg actual drug present in total microspheres (drug 1gm+ 
excipients) is calculated. That amount mixed in 0.1 M HCL by sonication. From that 
pipette 1ml into 10ml volumetric flask and made upto 10ml using buffer. The solution 
was filtered and the absorbance was measured after suitable dilution 
spectrophotometrically at 296 nm against appropriate blank. The amount of drug 
entrapped in the microspheres was calculated by the following formulae.   
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                    Amount of drug actually present 
Percentage drug entrapment=  X 100 
                                                         Theoretical drug load expected 
The results are given in results and discussion. 
 
 d) Buoyancy studies 
 Microspheres (300mg) were spread over the surface of a USP XXIV dissolution 
apparatus type II filled with 900 ml of 0.1 M HCL. The medium was agitated with a 
paddle rotating at 75 rpm for 12 h. The floating and the settled portions of microspheres 
were recovered separately. The microspheres were dried and weighed. Buoyancy 
percentage was calculated as the ratio of the mass of the microspheres that remained 
floating and the total mass of the microspheres. 
  
     
% Buoyancy =  X 100 
( + ) 
Where, 
 = weight of the floating 
= settled microspheres respectively. 
 The results are given in results and discussion. 
 
e) Invitro dissolution studies  
Preparation of buffer solution 
Measure 4 ml of concentrated Hydrochloric acid, in a 1000ml volumetric flask 
and make up the volume upto 1000ml using distilled water and stir until it mix. 
In-vitro release profile: 
Medium : 0.1 M HCL  
Apparatus : USP II (Paddle) 
Speed  : 75 rpm 
Time  : 1hr, for every 2hrs up to 12hr  
Temperature : 37.5 °C                                                                                                                   
λ max  : 296 nm 
Perform the test on microspheres place in each dissolution vessel containing 
900ml of 0.1 M HCL maintained at 37 °C ± 0.5 °C. At specified time withdrawn required 
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amount the sample and replace the same amount with (maintain sink conditions) 
phosphate buffer, then absorbance was taken and calculate percentage release. 
   Absorbance × 900 × dilution              
% Purity=× 100 
       Slope × 1000 × label claim. 
 
f) Kinetics of drug release 
          The invitro dissolution profile of all batches were fitted to Zero order, First 
order,Higuchi model, Korsemeyer-peppas model to ascertain the kinetic modeling of 
drug release. Correlation coefficient ( ) values were calculated for linear curves 
obtained by the regression analysis of the above plot. 
Zero-order kinetic model –Cumulative % drug released vs. time 
First order kinetic model -log cumulative % drug remaining vs. time 
Higuchi model -Cumulative % drug released vs. square root of time 
Korsemeyer-peppas model -log cumulative % drug released vs. log time 
Zero order- kinetic model 
                            Zero order release would be predicted by the following equation.  
 
        Where, 
   -               Drug release at time‘t’ 
-               Initial drug concentration 
   -               Zero order rate constant ( ) 
      When the data plotted as cumulative % drug release time and the plot is linear , 
then the data obeys Zero-order equal to . 
 
First order kinetics 
     First order release would be predicted by the following equation 
 
 
 
Where, 
Log C -         Amount of drug remained at time ‘t’ 
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 -         initial drug concentration 
K        -        first order rate constant ( ) 
      When the data plotted as log cumulative % remaining time yields a straight line, 
then the release obeys first order kinetics. The constant ‘K’obtained by multiplying 2.303 
with the slope values.  
 
Korsemeyer-peppas model. 
        To study the mechanism of drug release from microspheres, the invitro data were 
fitted to the well known exponential equation (korsemeyer peppas model ) which is often 
used to describe the drug release behavior from polymeric systems. 
 
Where,  
              Mt/Mα -    The fraction of drug released at ‘t’ 
              K          -     Constant incorporating structural and geometrical characteristics of  
the drug / polymer system  
               n         -        Diffusion exponent related to mechanism the drug release 
When the data plotted as log % drug released log time yields a straight line with a 
slope equal to ‘n’ and the K can be obtained by y- intercept. 
Mechanism of drug release as per korsemeyer-peppas equation / peppas model 
Table 13.Mechanism of drug release 
 
S . No 
 
n values 
 
Drug release 
 
1 
 
0-0.5 
 
Fickian release 
 
2 
 
0.5-1.0 
 
Non-Fickian release 
 
3 
 
>1.0 
 
Class II transport 
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g) IR spectroscopy (Drug excipient compatibility 
FT‐IR spectrocopy was found to be the most reliable technique for predicting the 
possible interaction between the drug and polymers. The IR spectra of physical mixtures 
were studied using KBr disc method. 
 
h) Scanning Electron Microscopy 
              The morphological study was carried out by Scanning Electron Microscope 
(SEM). Microspheres were scanned and examined under Electron Microscope BRUKER 
HTS-XT. The sample was loaded on copper sample holder. 
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12. RESULTS AND DISCUSSIONS 
 
PRE FORMULATION STUDIES 
Organoleptic properties 
            These tests were performed as procedure given, Preformulation part. The results 
are illustrated in following table. 
Table 14. Organoleptic properties 
Test Specifications/limits Observations 
Color White to off white Off White powder 
Odour odorless odorless 
The results complies as per specifications 
 
Angle of repose 
             It was determined as per procedure preformulation in material and method part. 
The results are illustrated in following table. 
Table 15. Flow properties 
Material Angle of repose 
Abacavir sulphate 29°.28” 
 The result shows that drug having poor flow 
 
Bulk density and tapped density. 
             It was determined as per procedure given preformulation in material and method 
part. The results are illustrated in table. 
Table 16. Density 
Materials Bulk Density(gm/ml) Tapped density(gm/ml) 
Abacavir sulphate 0.19 0.26 
 
Powder compressibility 
             It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in table. 
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Table 17. Powder compressibility 
Material Compressibility index Hausner ratio 
Abacavir sulphate 28.04% 1.34 
The results shows that drug having poor flow property 
 
Melting point 
             It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in following table. 
Table 18. Melting point 
Material Material point range result 
Abacavir sulphate 165 °C Complies 
 The result complies as per specification. 
 
SOLUTION PROPERTIES 
pH of the solution 
             It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in following table. 
 
Table 19. pH 
Material Test Specification Observation 
Abacavir sulphate pH 7.5 7.5 
The result complies as per specification 
 
Solubility 
It was determined as per procedure given in preformulation in material and 
method part. The results are illustrated in following table. 
 
Table 20. Solubility 
Test Specification Result 
solubility 
Freely soluble in water, Sparingly 
soluble in DMSO, 
ethanol, methanol 
Complies 
The result complies as per specification. 
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DRUG-EXCIPIENT COMPATABILITY STUDIES 
 Discussion:  
Drug excipient interactions play a vital role with respect to release of drug from 
formulation amongst others. FTIR techniques have been used here to study the physical 
and chemical interaction between drug and excipient used.  
 
Table 21. Drug – Excipients Compatibility Study Results 
Drug + Excipients Initial 
After 1 month at 
Compatible 
400C/75%RH 600C 
Drug  White powder No change No change   Yes 
Drug + Methanol White powder No change No change Yes 
Drug + Tween 80 White powder No change No change Yes 
Drug + HPMC K100M White powder No change No change Yes 
Drug + HPMC K4M White powder No change No change Yes 
Drug + Dichloro 
methane 
White powder No change No change Yes 
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IR GRAPHS 
 
 
Fig. 13(a) FT-IR of Abacavir Sulphate  
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Fig. 13(b) FT-IR Graph of HPMC K4M 
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Fig. 13(c) FT-IR Graph of HPMC K100M 
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Fig. 13(d) FT-IR Graph of Mixture of  
Abacavir Sulphate + HPMC K4M +HPMC K100M 
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Table.No.22: Band  Assignments for the Infrared Absorption Spectrum                              
of Abacavir Sulphate 
Band Energy  (cm-1) Assignment 
3463.2 
2958.6 
2849.7 
1660.0 
1451.6 
tertiary amine hydrochloride (N-H) stretch 
O-H stretch 
C-H Stretch 
Cyclopentene Ring C=C stretch 
C-H Bending (CH2 Scissoring) 
 
In the present study, it has been observed that there is no chemical interaction 
between Abacavir sulphate and the polymers used. From the figures 11(a),11(b),11(c) 
and 11(d) it was observed that there were no changes in these main peaks in IR spectra of 
mixture of drug and polymers, which show there were no physical interactions because of 
some bond formation between drug and polymer.  
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Table.No. 23.  EVALUATION OF MICROSPHERES 
Batch 
NO. 
Angle of 
Repose(°) 
Bulk 
Density 
(g/ml) 
Tapped 
Density(g/ml) 
Carr’s 
Index 
(%) 
Huasner 
Ratio 
F1 25°08′ 0.2826 0.3177 10.38 1.11 
F2 23°52′ 0.2671 0.3242 14.07 1.19 
F3 24°24′ 0.2841 0.3318 16.47 1.15 
F4 27°62′ 0.2853 0.3420 16.13 1.19 
F5 24°09′ 0.2965 0.3446 14.47 1.16 
F6 27°37′ 0.2924 0.3321 11.94 1.13 
F7 26°64′ 0.2768 0.3394 13.68 1.22 
F8 24°71′ 0.2891 0.3503 16.04 1.21 
F9 26°14′ 0.2965 0.3446 13.54 1.16 
F10 25°50′ 0.2721 0.3242 15.07 1.19 
Discussion 
The angle of repose for the formulations F1-F10 was found to be in the range 23°52′ to 
27°62′ shows good flow property 
          Compressibility index for the formulations F1-F10 found between 10.38% to 
16.13% indicating the good flow property. 
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Table 24.PERCENTAGE YIELD, INVITRO BUOYANCY, DRUG ENTRAPMENT  
EFFICIENCY OF FLOATING MICROSPHERES OF ABACAVIR SULPHATE 
Batch No. Percentage yield Invitro buoyancy Entrapment efficiency 
F1 84.52 85.65 82.60 
F2 82.98 83.75 81.73 
F3 83.54 84.82 82.17 
F4 79.89 80.23 78.61 
F5 85.15 86.24 83.04 
F6 88.91 89.54 87.39 
F7 90.21 91.66 88.69 
F8 86.78 87.26 83.92 
F9 85.59 86.92 83.47 
F10 87.66 88.22 85.21 
 
Fig.No. 14:  Buoyancy, Entrapment efficiency Study of Floating Microspheres 
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Percentage yield  
         The maximum percentage yield was found in F7 formulation and was noted to be 
90.21 % among all formulations.  
 
        The floating microspheres were prepared with different and combination of two 
polymer of  HPMC K4M, HPMC K100M, Sodium Alginate and Sodium CMC to 
investigate the influence of  encapsulation efficiency and were used to determine its 
influence on floating behavior. 
Invitro Buoyancy  
Discussion  
          The different polymers with same ratios of formulation were selected for 
optimization of their buoyancy property. The formulations in which combination of 
HPMC K4M, HPMC K100Mare giving the better results. 
           The formulations, are selected as the best formulations depending upon their 
buoyancy, encapsulation efficiency. From the results of all the ten formulations, it is 
confirmed that the change in polymers of Sodium Alginate, Sodium CMC, HPMC K4M, 
K100M influences the properties of the formulations. The formulation F7 with drug and 
combination of two polymer 1:1 ratio, is giving the best result of buoyancy property. 
            The microspheres, having lower densities (having a hollow core) exhibited 
buoyancy and are expected to be retained in gastric environment for more than 12 hrs. 
This may be attributed to a decrease in density of microspheres with an increase in 
polymer concentration. 
Fig.No. 15:  Buoyancy Study of Floating Microspheres 
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Entrapment efficiency 
Discussion  
          The percentage entrapment efficiency of various formulation parameters of the 
prepared microspheres were shown in table. The entrapment efficiency varied from 78.61 
to 88.69. 
The formulation F7 is having high encapsulation efficiency of 88.69% and F4 is having 
low encapsulation efficiency of 78.61%. 
           The low encapsulation is because of using single polymer of HPMC K100M than 
the drug concentration where the quantity of HPMC K100M is insufficient to entrap the 
drug. The high encapsulation efficiency is because of using combination of polymers of 
HPMC K100M, HPMC K4 where the increase in the HPMC concentration forms larger 
microspheres encapsulating more amount of drug. 
Table 25. INVITRO RELEASE PROFILE 
Time 
(hours) 
BATCH NO. 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
1 20.03 12.05 14.18 10.01 12.91 10.56 8.25 15.23 12.11 9.54 
2 35.56 32.56 31.56 28.19 22.12 15.99 13.11 25.76 22.77 13.84 
4 54.14 53.29 45.25 62.43 35.12 28.21 24.72 37.45 30.99 24.15 
6 69.65 77.38 63.14 76.37 52.64 44.14 40.99 53.28 48.12 43.09 
8 89.14 96.38 92.02 98.24 78.11 58.98 56.25 79.54 69.82 54.69 
10     94.42 78.68 72.84 90.47 93.51 72.74 
12      87.04 90.12   85.25 
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Fig.16. Invitro Dissolution Release Profile for F1 – F10 Formulations 
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Fig.17. Invitro Dissolution Release Profile for F1 – F5 Formulations 
 
 
 
Fig.18. Invitro Dissolution Release Profile for F6 – F10 Formulations 
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Fig.19. Invitro Dissolution Release Profile for Best Formulation F7 
 
Discussion: 
From the Invitro dissolution study of all formulations ( F1-F10), formulation F7 
release around 90.12% of drug at the end of 12 hours for a sustained release. Therefore 
the F7 formulation chosen as the best formulation from all ten batches.  
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Kinetics of drug release : 
Table 26. Drug release kinetics of formulation F7 
Time 
(Hr) 
cumulative 
% drug 
released 
% drug 
remaining 
Square 
root 
time 
log Cumu 
% drug 
remainining 
log 
time 
log 
Cumu 
% drug 
released 
0 0 100 0.000 2.000 0.000 0.000 
1 8.25 91.75 1.000 1.963 0.000 0.916 
2 13.11 86.89 1.414 1.939 0.301 1.118 
4 24.72 75.28 2.000 1.877 0.602 1.393 
6 40.99 59.01 2.449 1.771 0.778 1.613 
8 56.25 43.75 2.828 1.641 0.903 1.750 
10 72.84 27.16 3.162 1.434 1.000 1.862 
12 90.12 9.88 3.464 0.995 1.079 1.955 
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Fig. 20. ZERO ORDER KINETIC MODEL 
 
 
Fig. 21. ZERO ORDER KINETIC MODEL 
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Fig. 22. ZERO ORDER KINETIC MODEL 
 
 
Fig.23. KORSEMEYER PEPPAS MODEL 
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Table 27. Regression Coefficient of F7 
 
Formulation 
Regression coefficient ( ) values 
Zero order First Order Higuchi Model 
Korsemeyer -
peppas 
Abacavir 
sulphate Floating 
Microspheres 
0.9955 0.8278 0.8945 0.8400 
 
n = 0.9735 
 The regression coefficient values and n values show that the drug releases follow 
Non - Fickian release (Diffusion and swelling). 
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Scanning Electron Microscopy (SEM) 
Fig 24 (a)                        
 
Fig 24 (b) 
 
 Fig 24(c) 
Fig. 24 Scanning electron microphotographs of floating microsphere of Abacavir 
sulphate:24(a) &24(b) smoothness of the surface of spherical shaped microsphere 
24(c) Internal view of the shell having porous structure. 
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DISCUSSION 
 Morphology of floating microspheres was examined by scanning electron 
microscopy. The view of the microspheres showed hollow structure with a smooth 
surface morphology exhibited range of sizes within each batch. The outer surface of 
microspheres was smooth and dense, while the internal surface was porous. The shell of 
microspheres also showed some porous structure it may be caused by evaporation of 
solvent entrapped within the shell of microsphere after forming smooth and dense layer. 
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13. SUMMARY 
             The present study involves formulation and evaluation of sustained release 
floating microspheres of Abacavir sulphate. Endeavour’s with respect to floating 
mechanism are inculcated in the formulation to achieve longer stay of microsphere in 
stomach which happen to better site of absorption for the selected drug.   
              Preformulation studies involving organoleptic bulk density, tapped density, 
angle of repose, compressibility of index, hausner ratio, melting point range, pH, 
solubility were carried out as per IP specification. 
                Drug excipient compatibilities were carried out and evaluation and FT-IR, 
SEM.  This showed no significant change in any way to the Mixture. 
               Different polymers like sodium alginate, sodium carboxy methyl cellulose, 
HPMC K4M, HPMC K100M were utilized in the trials. All the physical evaluations are 
carried in preformulation studies were carried out on all the three different polymers 
utililized. All the formulations exhibited values within the acceptable range. 
                Microspheres were evaluated for buoyancy studies, drug entrapment efficient. 
               Release studies were carried out in 0.1N HCL for 12 hours. Evaluated samples 
for all the four polymer system. Results indicated that formulation F7, gave 90.12 % 
release up to 12 hrs which is formulated with HPMC K100M and HPMCK4M 
combination. Assay was carried out for formulation F7 and was found to be 88.69 %. The 
mechanism of drug release from microspheres follows Non-Ficknian release. 
               Remaining formulations gave fluctuating release profiles. The formulation F7 
was considered to be better among the trails accomplished.  
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14. CONCLUSION 
            The ultimate goal for sustained drug release is to maximize therapeutic activity 
while minimizing the negative side effects of the drug. In this regard, floating 
microspheres have emerged as a novel drug delivery system to treat HIV with Abacavir 
sulphate.  
 
The type of polymer affects the drug release rate and the mechanism. Polymer 
swelling is crucial in determining the drug release rate and is also important for flotation. 
A lesser FLT and a prolonged floating duration could be achieved by using different 
polymer combinations. In this study sustained release Floating Microsphere approach for 
Abacavir sulphate purposes that with hydrophilic polymers the GI retention can be 
enhanced and reduce frequency of dosing, thereby minimizing the occurrence of side 
effects, site specificity, increase the effectiveness of the drug and better patient 
compliance This gives a signal to extending this approach to similar combinations of 
drugs used in clinical practice so as to improve bioavailability of poorly absorbed drugs 
in GIT.  
 
When these floating microspheres compared to other floating dosage forms like 
floating tablets have bulk density less than gastric fluid and so remain buoyant in the 
stomach for prolonged period of time and these are used as multiunit dosage form and 
drug release optimization and show efficiency level. So, Sustained release floating 
microspheres of Abacavir sulphate may provide a convenient dosage form for achieving 
best performance and release and show good bioavailability. 
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